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1. ABSTRACT 
 
There is no health system in place to deliver the affordable drugs that can treat and prevent the 
disease burden for those in need. Cardiovascular disease is ravaging India and China. 
Unfortunately, though, the people of such low- and middle-income countries (LMIC) are not 
able to access preventive treatments widely available in the West. Cardiovascular disease was 
the leading cause of death globally in 2005 with more than 80 per cent of these deaths 
occurring in LMIC. In China, stroke, chronic obstructive airways diseases, cancer and heart 
disease are the four highest contributors to the country’s total disease burden almost half of 
these are due to cardiovascular disease. Cardiovascular drugs include antihypertensives, 
antihyperlipidemics, vasodilators, anticoagulants, diuretics and other Agents. 1a According to 
World Health Report 2002, cardiovascular diseases (CVDs) will be the largest cause of death and 
disability by 2020 in India (WHO 2004). 8  
Hypertension damages blood vessels in kidney, heart, and brain and leads to an increased 
incidence of renal failure, coronary disease, cardiac failure, and stroke. Hypertension is a major 
risk factor for two distinct kinds of vascular problems: Complications of atherosclerosis 
including myocardial and cerebral infraction as well as complications of small vessel disease 
including renal failure, intracerebral hemorrhage and lacunar infractions. 17 
Therapy using the antihypertensive agents evolved rapidly between 1950 and 1960. During that 
time a number of empiric discoveries were made that resulted in the marketing of the drugs for 
the treatment and control of hypertensive diseases. The conventional treatment for the 
hypertension includes various drugs from the categories of diuretics, β-blockers, calcium 
channel blockers, ACE Inhibitors, Type-1 angiotensin II receptor antagonists, α1 Adrenoceptor 
antagonists, vasodilators etc. 19   
Antagonism of β-adrenergic receptors affects the regulation of the circulation through a 
number of mechanisms, including a reduction in myocardial contractility, heart rate, and 
cardiac output. An important consequence of using β - adrenergic receptors is blockade of the β 
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receptors of the juxtaglomerular complex, reducing renin secretion and thereby diminishing 
production of circulating angiotensin II. This action likely contributes to the antihypertensive 
action of this class of drugs, in concert with the cardiac effects.  
Propranolol is the proto type agent for class of β - adregernic bloking agents. Propranolol has 
equal affinity for β1 and β2 adrenergic receptors; thus, it is a nonselective β adrenergic receptor 
antagonist. Propranolol is a pure antagonist, lacks intrinsic sympathomimetic activity. 21 
Because all β adrenergic receptor antagonists are effective antihypertensive agents and (+)-
propranolol, the inactive isomer that has little β-adrenergic receptor blocking activity, has no 
effect on blood pressure, the antihypertensive therapeutic effect of these agents is 
undoubtedly related to receptor blockade.22 
In medicinal chemistry, the chemist attempts to design and synthesize a medicine or a 
pharmaceutical agent which will benefit humanity. Recently, several clinical trials have 
demonstrated that beta-blockers remarkably reduced mortality in patients with moderate 
heart failure as well as improved the quality of life and sense of well-being by reducing 
hospitalizations and arrhythmias. 24 This name originates from the presences of an –OCH2- 
group located between a substituted aromatic ring and an ethylamino side chain of pronethalol 
(1). The aromatic ring and substituents are the primary determinants of β antagonist selectivity. 
Propranolol (2), nadolol (3), timolol (4) and pindolol (5) are non-specific β blokers whereas para 
position substitutions on the aromatic rings of metoprolol (6), atenolol (7), esmolol (8), 
acebutolol (9) both confer β1 antagonist selectivity.
25  
The concept of alkyl aminohydroxypropoxy (10) side chain derivatives is understood by class of 
β – adrenergic blocking agents. Researchers who were studying the effects of aryl ring and aryl 
substitution in the molecule tried to modify the ethanolamine chain itself by inter alia, the 
introduction of linking group between aryl ring and ethanolamine chain. After lots of linking 
groups tried, the best linking group comes out to be oxymethylene. It is first analog, 
propranolol which is the most widely used β - blocker now and is 10 to 20 times potent than its 
parent compound pronethalol.26 
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Thromboembolism is the combination of thrombosis and its main complication, embolism. 
When a thrombus occupies more than 75% of surface area of the lumen of an artery, blood 
flow to the tissue supplied is reduced enough to cause symptoms because of decreased oxygen 
(hypoxia) and accumulation of metabolic products like lactic acid. More than 90% obstruction 
can result in anoxia, the complete deprivation of oxygen, and infarction, a mode of cell death. 
The symptoms of a thromboembolism depend on the organ or blood vessel that has lost blood 
supply. Blood clots in an arm or leg may cause pain, swelling, and increased temperature in the 
affected area. A clot that travels to the lung is called a pulmonary embolus. This condition can 
cause: chest pain, shortness of breath, rapid heartbeat, known as tachycardia, fainting or death. 
If a blood clot is formed in the heart, it can travel to almost any organ in the body. This could 
cause a stroke, which is a type of damage to the brain from lack of blood circulation. In other 
cases, damage may be done to an arm or leg, or a heart attack or kidney damage may occur. 
Other areas of the body can also be affected.  
An anticoagulant is a substance that prevents coagulation; that is, it stops blood from clotting. 
Anticoagulants were introduced into medical practice more than three decades ago. Extensive 
use of these drugs in the prevention and treatment of thromboembolic disease has made them 
one of the most widely used classes of pharmacological agents.  
Anticoagulant drugs include:  
a) Heparin and derivative substances e.g. Low molecular weight heparin  
b) Vitamin K antagonists e.g. Warfarin  
Warfarin and related 4-hydroxycoumarin-containing molecules decrease blood coagulation by 
inhibiting vitamin K epoxide reductase, an enzyme that recycles oxidized vitamin K to its 
reduced form after it has participated in the carboxylation of several blood coagulation 
proteins, mainly prothrombin and factor VII.  
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The story of the coumarin anticoagulants generally is traced back to the early 1920s, when the 
"sweet clover disease" showed up almost simultaneously in North Dakota and in Alberta, 
Canada. This new malady of cattle involving fatal bleeding was traced to stacks of sweet clover 
hay.29 Thousands of synthetic equivalents were prepared in 1940. Since 1940, hundreds of 4-
hydroxycoumarin-based compounds have been prepared and tested for anticoagulant activity, 
among these; Warfarin quickly became the leader in clinical anticoagulant therapy. Coumarin 
has a characteristic hay-like, sweet aromatic creamy odor with certain nutty shadings, much 
used in synthetic form as a fragrance chemical for various products like toothpastes, 
antiperspirant deodorants, bath products, body lotions, face creams, fragrance creams, hair 
sprays, shampoos, shower gels and toilet soaps. Coumarin has been used in detergents as a 
brightener or bleaching agent. It is used as an odor-enhancer to achieve  a  long-lasting  effect  
when  combined  with  natural  essential  oils  such  as lavender, citrus, rosemary and oak moss. 
Marshall et al. (1987) stated that coumarin has been recommended for treatment of a number 
of clinical conditions, including high protein edema and brucellosis. Kontogiorgis et al. (2005) 
stated the anti inflammatory and antioxidant activity of novel coumarin derivatives. Anamik et 
al. (2005) synthesized series 4-hydroxy derivatives and screened them in vitro for anti-HIV 
activity against HIV-1(IIIB) and HIV-2(ROD) virus strains. Compound (41) was found to be the 
most active.112 Shen et al. (2010) worked on hydroxycoumarin derivatives as novel and potent 
α-Glucosidase Inhibitors, hence use as insecticide. 
The main complications of hypertension, i.e. coronary heart disease, ischemic strokes and 
peripheral vascular disease (PVD), are usually related to thrombosis. Increasing evidence also 
suggests that hypertension fulfils the components of Virchow's triad, thus conferring a 
prothrombic or hypercoagulable state, as evident by abnormalities of haemostasis, platelets 
and endothelial function. It therefore seems plausible that use of antithrombotic therapy may 
help prevent these thrombosis-related complications of hypertension. Indeed, hypertensive 
patients with an estimated 10-year CHD risk > or = 15% will have their cardiovascular risk 
reduced by 25% using antihypertensive treatment, but the addition of aspirin further reduces 
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major cardiovascular events by 15%. Recent guidelines recommend the use of aspirin 75 mg 
daily for hypertensive patients who have no contraindication to aspirin.35 In addition it should 
be recognized that some of the complications related to elevated blood pressure, heart failure 
or atrial fibrillation, are themselves associated with thromboembolism.37 Increasing evidence 
also points towards a prothrombic or hypercoagulable state conferred by the presence of 
elevated blood pressure, as evident by abnormalities of coagulation, platelets and endothelial 
function in such patients.38-39 
It therefore seems plausible that use of antithrombotic therapy may be of particular benefit in 
preventing the thrombosis-related complications of elevated blood pressure.40 The 
antithrombotic agent, acetylsalicylic acid (ASA), is established as an effective agent for 
secondary prevention in patients with proven occlusive vascular disease.41 However, it is not 
recommended for primary prevention and it is unclear whether it has a role in patients with an 
increased risk of thrombotic complications such as those with elevated blood pressure. 
Warfarin has also been found to be useful as thromboprophylaxis in patients with elevated 
blood pressure and atrial fibrillation; however, if blood pressures remain uncontrolled, such 
therapy carries significant risk, especially from intracranial hemorrhage. 
Thus, since hypertension and thrombo-embolism are intricately involved in pathophysiological 
changes and progression of cardio-vascular diseases; antihypertensive drugs like propranolol 
and anticoagulant drugs like Warfarin are frequently, combined in management of some types 
of hypertension. However, in clinical practice, it has been noted that prescribing, one drug with 
two different activities, improves patient compliance to the treatment instead of two drugs 
with two different activities resulting in better clinical outcome. Therefore, in the present 
project, we attempted to synthesize a single drug molecule with antihypertensive activity of 
propranolol and anticoagulant activity of Warfarin (Coumadin).  
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To achieve this, we attached alkylaminohydroxypropoxy side chain (responsible for 
antihypertensive activity of propranolol) to 4-Hydroxy coumarin nucleus (responsible for 
anticoagulant activity of Warfarin). Several resulting molecules were then, subjected to 
pharmacological evaluation, for both types of activities, to assess structure activity relationship 
and to ascertain the lead molecule.   
In our project, for synthesis of substituted 4-hydroxy coumarin nucleus, we used phenol, m-
cresol and p-cresol as starting materials. Thus, we synthesized 3 basic coumarin nucleus viz. 4-
hyddroxy coumarin, 7-methyl-4-hydroxy coumarin and 8-methyl-4-hydroxy coumarin nucleus, 
respectively. Each nucleus was then, reacted with epichlorhydrin to form three varieties of 
epoxy derivatives. Finally, each epoxy derivative was reacted with 10 different amines to form 
10 different coumarin molecules. All resulting 30 compounds, were then, converted to 
hydrochloride salts, by reacting them with dry hydrochloric acid gas.  
Bose et al synthesized 4-hydroxy coumarins by heating diaryl malonates with equimolor moles 
of corresponding malonic acid in the presence of about anhydrous ZnCl2 and POCI3. We 
attempted to carry out this reaction at 700C for 12-15 hours, but it was observed that maximum 
yield was obtained only after 16 hours. It was also noted that on acidification of sodium 
bicarbonate filtrate, at neutral point, the product precipitated out. The yield was increased, if 
acidified slurry was kept overnight. Hence, this modified version of reaction was adopted, for 
synthesis of all other coumarin derivatives, in our project. Our attempts to carry out reactions 
of other phenols like α-napthol, β-napthol and hydroxyl benzoic acid were unsuccessful. When 
4-hydroxy coumarin derivative was treated with epichlorhydrin in presence of base, under 
suitable condition, resulted in formation of the epoxy derivative. To obtain solid product, the 
epoxy resin was completely separated from reaction mixture, by using mother solvent i.e. 
toluene. Then semisolid mass was obtained. Semisolid mass was obtained only, when the 
solvent or unreacted amine was distilled out. When this product was dissolved in 1:5 mixture of 
DMF + dioxane then poured on to ice + water mixture, a free product (base) in aqueous 
medium obtained. But when it was filtered, it soon converted in to brown semisolid mass. 
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Synthesized compounds conformed to the spectral analysis. Infra Red Spectra were taken on 
Shimadzu FTIR-8400 Spectrometer, using KBr Pellet method. The characteristic peak of carbonyl 
group in coumarin moiety was observed at 1700-1722 cm-1 frequency, while C-O streching of  
ring skeleton was observed at 1160-1125 cm-1 frequency. The N-H streching of secondary amine 
gave a broad peak, between 3350-3300 cm-1 frequency. The C-N streching was observed at 
1250-1235 cm-1 frequency. The –OH bending was observed at 1380-1310 cm-1 frequency. Other 
frequencies, observed due to ring skeleton, were around 1600-1450 cm-1 frequency of C=C 
stretching and 2900-3000 cm-1 frequency, was due to C-H stretching. Further conformation of 
the molecular structure was evaluated by mass spectra. The mass spectrum of compounds 
were recorded by Shimadzu GC-MS-QP-2010 spectrometer. The molecular ion peak and the 
base peak, in all compounds, were clearly obtained in mass spectral study. The molecular ion 
peaks were found to be in agreement with molecular weight of the respective compounds. 
NMR Spectrum of compound BLT2, was taken which showed methylene (-CH2), amine (>NH), 
hydroxy (R-OH) methyl (-CH3) and aromatic protons (Ar-H) peaks. The values for methylene (-
CH2) proton was observed between 2.77 and 2.86 δ ppm. Aromatic protons showed the 
multiplet between 7.35-8.05 δ ppm. The singlet peak of  amine (-NH) was observed at  3.88-
3.91 δ ppm. The value of methyl proton (-CH3) was observed as singlet at 1.18 δ ppm. Multiplet 
were observed at 4.26-4.29 ppm of (-CH2CHCH2) proton and triplet was obtained at 4.16-4.22 
ppm due to (-CH2CH) group. 
For screening of anticoagulant activity, at the end of three weeks treatment, blood samples 
were collected from retro orbital plexuses under light ether anesthesia. The samples were 
collected in EDTA tube to prevent clot formation, at room temperature. Determination of 
clotting time was done, using Lee and white method 
From each coumarin derivative, 4 compounds were selected for screening. Our aim was to 
evaluate anticoagulant property followed by evaluation of antihypertensive activity. Warfarin- 
treated (0.1mg/kg p.o.) rats showed significant increase in bleeding and clotting time, as 
compared to normal control rats. Treatment with, all 12 test compounds (5ml/kg/day, p.o) also 
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produced significant increase in bleeding and clotting time, as compared to normal control rats.  
When subjected to pharmacological screening for anticoagulant activity and antihypertensive 
activity; all 12 synthesized compounds exhibited anticoagulant activity but highly significant 
anticoagulant activity was observed in compounds BLT 2, 8, 12, 18, 28 accompanied by increased 
bleeding and clotting time that was near to the standard drug viz. Warfarin, indicating that 7-
methyl and 8-methyl derivatives also possess anticoagulant activity. Substituted groups that 
contain four carbon atoms; if substituted at nitrogen atom, exhibit maximum activity. This goes 
to confirm that 4-hydroxycoumarin derivatives, have anticoagulant property and that there is 
no relation between substituted and unsubstituted coumarin derivatives. We believe that in 
coumarin class anticoagulant compounds, hydroxyl group of 4-Hydroxy coumarin plays 
important role in formation of cyclic structure through hydrogen bond, with side chain attached 
to 3rd carbon in coumarin nucleus e.g. Warfarin. In case of our compounds, hydrogen bond 
formation takes place between hydroxyl group of side chain and pi-electrons of alkenes in 
coumarin ring (3rd and 4th carbons) hence; cyclic structure is formed showing activity in all 
compounds that were tested. 
We believe that bulkier substitution on 3rd position of coumarin causes increase in 
anticoagulant activity, e.g. ferulenol. In our project, we found that more bulky groups like tert-
butyl (BLT 1) showed significant anticoagulant activity. Diethanol derived compounds BLT 8 and 
BLT 18, showed good activity for the same reason. Finally, we conclude that formation of ring 
structure in coumarin through hydrogen bonding and bulky groups at terminal part of the side 
chain are responsible for anticoagulant activity, in a compound.    
9 anticoagulant compounds were subjected to antihypertensive screening. Here, noradrenalin- 
treated (10mg/kg i. v.) rats showed significant increase in blood pressure. Treatment with test 
compounds (5mg/kg/day, i. v.) also produced antihypertensive action, but BLT 1, 2, 21 had 
significant effect as compared to others. 
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Compounds BLT 1, 2, 7, 11, 12, 17, 21, 22, 27 were evaluated for antihypertensive activity, using invasive 
method, on BioPac instrument. Results showed that Isopropyl and tert-butyl substituted 
compounds i.e. BLT 1, 2, 21 possess antihypertensive activity. While other compounds like BLT 7, 
11, 12, 17, 22, 27 did not show significant antihypertensive activity. We infer that increase in no. of 
carbon atoms, more than four, on amine substitution, is likely to cause decrease in 
antihypertensive activity. 
Thus, in the present project, we synthesized 30 coumarin derivative compounds, out of which, 
12 compounds exhibited anticoagulant activity, 9 among which also exhibited antihypertensive 
activity. Further, some of these 8 compounds exhibiting dual activity were 7-methyl substituted 
coumarins. Literature review reveals that carbon no. 7 in coumarin nucleus of Warfarin 
molecule is involved in its metabolism, before being excreted in urine. Hence, metabolism 
studies of these compounds may be planned as an extension of our work.   
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2. INTRODUCTION  
 
Cardiovascular diseases include a wide range of heart abnormalities, as well as diseases 
of other parts of the circulatory system, such as the coronary arteries, the 
cerebrovascular system, the aorta and pulmonary vessels, and the peripheral arteries 
and veins.1 Cardiovascular disease is ravaging India and China. Unfortunately, though, 
the people of such low- and middle-income countries (LMIC) are not able to access 
preventive treatments widely available in the West. Cardiovascular disease was the 
leading cause of death globally in 2005 with more than 80 per cent of these deaths 
occurring in LMIC.2 In China, stroke, chronic obstructive airways diseases, cancer and 
heart disease are the four highest contributors to the country’s total disease burden 
almost half of these are due to cardiovascular disease. Cardiovascular disease risk 
factors such as obesity, high blood pressure, tobacco smoking and diabetes, are on the 
increase in LMIC. India, as an example, has twice the mortality rate from cardiovascular-
related deaths among people of working age between 39 and 59 years, compared to 
the USA. Most patients in low- and middle-income countries have a choice between 
foregoing expensive treatment and taking financial ruin.3 There is no health system in 
place to deliver the affordable drugs that can treat and prevent the disease burden for 
those in need cardiovascular drugs include antihypertensives, antihyperlipidemics, 
vasodilators, anticoagulants, diuretics and other Agents.  
2.1  HYPERTENSION 
Hypertension is the most common cardiovascular disease and a silent epidemic of the 
20th century. According to the National Health Examination Survey of 1960 to 1962, 15 
percent of whites and 27 percent of blacks had hypertension based on the World 
Health Organization criteria (blood pressure above 140/90 mm of mercury). Despite 
availability of adequate treatment, most hypertensive persons have inadequately 
controlled blood pressure. Both a lack of awareness and lack of compliance contribute 
to the problems.4 The mortality associated with hypertension and hypertension-related 
myocardial infarctions, cerebrovascular accidents and renal failure account for more 
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than a million deaths per year in the United States. In addition, the morbidity associated 
with these diseases has been estimated to cost more than $5 billion a year.5  
The third National Health and Nutrition Examination Survey (NHANES III), conducted 
from 1992 to 1994, found that 27% of the USA adult population had hypertension.6 
Essential hypertension cannot be cured but can be controlled. Many individuals 
experience hypertension as they grow older, but hypertension is not a part of healthy 
aging. For many older individuals, the systolic pressure gives the most accurate 
diagnosis of hypertension. Geographical variations in cardiovascular diseases and 
associated risk factors have been recognized worldwide. Little attention has been 
directed to potential differences in hypertension between Europe and North America. 
Hypertension is more prevalent in Europe than United state and Canada. Average B.P. 
was 136/83mmHg in the European countries while in United States it is 127/77 mmHg.7 
According to World Health Report 2002, cardiovascular diseases (CVDs) will be the 
largest cause of death and disability by 2020 in India (WHO 2004). Reviews of studies on 
hypertension epidemiology in India have shown high prevalence in both urban and rural 
areas. Indian urban population studies from the mid 1950s to late 1990s used the older 
WHO guidelines for diagnosis (known hypertension or BP >160 mm Hg systolic and/or > 
95 mm Hg diastolic). A significantly increasing adult prevalence of hypertension has 
been reported changing from 4.4% in Agra (1961), 6.4% in Rohtak (1975), 15.5% in 
Bombay (1980), 14.1% in Ludhiana (1985), 11.0% in Jaipur (1995), 11.6% in Delhi (1997), 
and 13.1% in Chandigarh (1999). Although there is a lower prevalence of hypertension 
in rural Indian populations, there has been a steady increase over time here as well. 
Reddy et al. also reported high prevalence of hypertension in a study among industrial 
populations at multiple sites in India. These findings are in consonance with many 
developed countries where it has been reported that at any given time almost half of all 
individuals have high BP.8 
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The physiologic basis for essential hypertension is elevated peripheral resistance. 
Cardiac output is usually within normal limits. Only in a small minority of hypertensive 
patients is increased cardiac output the cause of hypertension. This subgroup of 
hypertensive patients tends to be younger and has a more labile pattern of blood 
pressure elevations.9-10  
The cause of most forms of hypertension is unfortunately not known. There is a 
likelihood that essential hypertension has multiple causes, although evidence to 
support this is lacking. Measurements of renin activity in hypertensive patients has 
received considerable attention recently, but categorizing patients by their renin levels 
has not improved blood pressure control and, at present, merely adds to the already 
skyrocketing cost of medical care.11-16 Hypertension damages blood vessels in kidney, 
heart, and brain and leads to an increased incidence of renal failure, coronary disease, 
cardiac failure, and stroke. Hypertension is a major risk factor for two distinct kinds of 
vascular problems: Complications of atherosclerosis including myocardial and cerebral 
infraction as well as complications of small vessel disease including renal failure, 
intracerebral hemorrhage and lacunar infractions.17 As a consequence of elevated 
blood pressure, arterial elasticity is reduced and wall damage appears which can lead to 
cholesterol and fat deposition on those lesions and eventually to obstruction of the 
vessels. This is the basis of most of the target organ damages induced by hypertension. 
At very high blood pressures (systolic 210 and/or diastolic 120 mm Hg), a subset of 
patients develops fulminant arteriopathy characterized by endothelial injury and a 
marked proliferation of cells in the intima, leading to intimal thickening and ultimately 
to arteriolar occlusion. This is the pathological basis of the syndrome of immediately 
life-threatening hypertension, which is associated with rapidly progressive 
microvascular occlusive disease in the kidney (with renal failure), brain (hypertensive 
encephalopathy), congestive heart failure, and pulmonary edema. 
Another consequence can be the increase in vascular resistance, which forces the 
pumping activity of the heart to maintain its role in nutrients and oxygen distribution. 
This work overload for the heart may induce the development of cardiac hypertrophy, 
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an increase in cardiac mass and thickness. Left ventricular hypertrophy defined by 
electrocardiogram, or more sensitively by echocardiography, is associated with a 
substantially worse long-term outcome that includes a higher risk of sudden cardiac 
death. The risk of cardiovascular disease, disability, and death in hypertensive patients 
also is increased markedly by concomitant cigarette smoking, diabetes, or elevated low-
density lipoprotein; the coexistence of hypertension with these risk factors increases 
cardiovascular morbidity and mortality to a degree that is compounded by each 
additional risk factor. Since the purpose of treating hypertension is to decrease 
cardiovascular risk, other dietary and pharmacological interventions may be required.18  
2.1.1  Antihypertensive Agents 
Therapy using the antihypertensive agents evolved rapidly between 1950 and 1960. 
During that time a number of empiric discoveries were made that resulted in the 
marketing of the drugs for the treatment and control of hypertensive diseases. 
Nonpharmacological therapy is an important component of treatment of all patients 
with hypertension. In some stage 1 hypertension, blood pressure may be adequately 
controlled by a combination of weight loss (in overweight individuals), restricting 
sodium intake, increasing aerobic exercise, and moderating consumption of alcohol. 
These lifestyle changes, though difficult for many to implement, may facilitate 
pharmacological control of blood pressure in patients whose responses to lifestyle 
changes alone are insufficient. 
The conventional treatment for the hypertension includes various drugs from the 
categories of diuretics, β-blockers, calcium channel blockers, ACE Inhibitors, Type-1 
angiotensin II receptor antagonists, α1 -adrenoceptor antagonists, vasodilators etc. 
                                                                                 Introduction 
 
Page 14 
 
 
Fig. 1 Target for Antihypertensive Treatment19 
 
Class of drugs Mode of action Adverse reactions 
β-adrenoceptor  antagonists 
(propranolol, atenolol,  
metoprolol) 
Receptor blockade–
decreased cardiac output 
and peripheral vascular 
resistance 
Bronchoconstriction, 
fatigue, depression, 
nightmares 
ACE Inhibitors 
(captopril,  lisinopril,  
enalapril) 
Inhibits angiotensin 
converting enzyme–
reduces the formation of 
Ang-II 
Chronic cough, 
hyperkalemia, first dose 
hypotension, renal failure 
Centrally acting drugs 
(clonidine, methyl dopa) 
Stimulates α2-
adrenoceptor –inhibits 
Dryness of mouth, 
drowsiness, depression, 
Table- 1 Various Classes of Drugs for the Treatment of Hypertension19  
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Arterial pressure is the product of cardiac output and peripheral vascular resistance. 
Drugs lower blood pressure by actions on peripheral resistance, cardiac output, or both. 
Drugs may reduce the cardiac output by inhibiting myocardial contractility or by 
decreasing ventricular filling pressure. Reduction in ventricular filling pressure may be 
achieved by actions on the venous tone or on blood volume via renal effects. Drugs can 
reduce peripheral resistance by acting on smooth muscle to cause relaxation of 
resistance vessels or by interfering with the activity of systems that produce 
constriction of resistance vessels (e.g., the sympathetic nervous system). 
 In patients with isolated systolic hypertension, complex hemodynamics in a rigid 
arterial system contribute to increased blood pressure; drug effects may be mediated 
by changes in peripheral resistance but also via effects on large artery stiffness 
The hemodynamic consequences of long-term treatment with antihypertensive agents 
provide a rationale for potential complementary effects of concurrent therapy with two 
or more drugs. The simultaneous use of drugs with similar mechanisms of action and 
hemodynamic effects often produces little additional benefit. However, concurrent use 
of drugs from different classes is a strategy for achieving effective control of blood 
pressure while minimizing dose-related adverse effects.   
release of norepinephrine rebound hypertension 
Diuretics 
(hydrochlorothiazide 
frusemide, spironolactone) 
Sodium excretion, volume 
depletion 
Urinary frequency, gout, 
Glucose intolerance,  
hypokalemia, 
thrombocytopenia 
Calcium channel blockers 
(verapamil, diltiazem, 
amlodipine, nifedipine) 
Relaxes vascular smooth 
muscles–decreases 
Peripheral vascular 
resistance 
Edema, dizziness, nausea, 
palpitation 
α1-Adrenoceptor antagonists 
(prazosin,terazosin,doxazosin) 
α1-Adrenoceptor 
blockade–vasodilatation 
Postural hypotension,  
Paroxysmal tachycardia, 
nightmares 
Angiotensin II receptor 
antagonists 
(losartan,Valsartan) 
Block angiotensin-II 
receptor on the arteries 
hyperkalemia, first dose 
hypotension 
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It is generally not possible to predict the responses of individuals with hypertension to 
any specific drug. For example, for some antihypertensive drugs, on average about two-
thirds of patients will have a meaningful clinical response, whereas about one-third of 
patients will not respond to the same drug. There is considerable interest in identifying 
genetic variation in order to improve selection of antihypertensive drugs in individual 
patients. Polymorphisms in a number of genes involved in the metabolism of 
antihypertensive drugs have been identified, for example in the CYP family (phase I 
metabolism) and in phase II metabolism, such as catechol-O-methyltransferase. While 
these polymorphisms change the pharmacokinetics of specific drugs, it is not clear that 
there will be substantial differences in efficacy given the dose range available clinically 
for these drugs.  
One of the biggest problems in the treatment of hypertension is patient compliance. It 
would seem logical that improving compliance would improve the overall treatment of 
hypertension. Because all drugs have side effects, it is important to individually tailor 
therapy to minimize discomfort to each patient. However, the patient must take 
responsibility for his illness and realize that his life-style may have to be altered slightly 
if he is to live longer. One basic principle that should apply to all drug therapy is that the 
less frequently a drug is taken, the more likely it is that the drug will be taken. Thus, a 
once-a-day regimen is better than twice daily, but twice a day is better than four times 
a day. Because almost all antihypertensive drugs can be given twice per day, 
compliance from this point of view should be good. Also, the fewer the drugs used to 
control blood pressure, the easier will be compliance. If blood pressure could be 
controlled using one drug once a day, overall compliance would be expected to 
improve. 
Another major problem in treating hypertensive patients is that most of them are 
asymptomatic; however, annoying side effects develop after initiation of drug therapy. 
Unless patients are well educated about the consequences of hypertension, it is easy to 
understand why many do not continue to take their medication. Implementing some 
self-assessment of blood pressure control has been shown to be helpful in overall 
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compliance.20 If a patient were to record his own blood pressure two times a day, not 
only would the physician get a better idea of his patient's hypertensive control, but the 
patient also would have some concrete goals to work towards that he could assess each 
day. This form of self-assessment of control would be similar to that practiced by 
diabetic patients who check urine glucose levels. 
Recommendations for specific drugs in treating hypertension are difficult to make 
unless the overall life-style and habits of each patient are evaluated individually. 
Obviously, if a patient makes his living as a bus driver, drugs like methyldopa and 
clonidine will be inappropriate because of central depressive effects. A patient who is 
athletically active may not do well taking high doses of propranolol because of the 
drug's ability to inhibit exercise-induced tachycardia. However, this same patient may 
find low doses of propranolol combined with a peripheral vasodilator to be a 
satisfactory regimen. In a patient with adult-onset diabetes this condition may be made 
worse by thiazide diuretics because the drugs interfere with insulin release. Yet, pro-
pranolol may be effective in such a patient. On the other hand, an insulin-dependent 
diabetic patient may find the use of propranolol unacceptable because it interferes with 
the warning signs and symptoms of hypoglycemia. Ideally, an antihypertensive regimen 
should be simple (one or two drugs, twice a day) and each patient should be made 
aware of possible side effects of the drugs before beginning therapy. Patients should 
actively participate in monitoring the control of their illness. And physicians should 
work with patients so that together they can control blood pressure with the fewest 
drug side effects. 
2.1.2  β-Blockers 
2.1.2.1  Pharmacology 
 Antagonism of β-adrenergic receptors affects the regulation of the circulation through 
a number of mechanisms, including a reduction in myocardial contractility, heart rate, 
and cardiac output. An important consequence of using β - adrenergic receptors is 
blockade of the β receptors of the juxtaglomerular complex, reducing renin secretion 
and thereby diminishing production of circulating angiotensin II. This action likely 
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contributes to the antihypertensive action of this class of drugs, in concert with the 
cardiac effects.  
The β-adrenergic blockers vary in their lipid solubility, selectivity for the β1-adrenergic 
receptor subtype, presence of partial agonist or intrinsic sympathomimetic activity, and 
membrane-stabilizing properties. Despite these differences, all of the β adrenergic 
receptor antagonists are effective as antihypertensive agents. However, these 
differences do influence the clinical pharmacokinetics and spectrum of adverse effects 
of the various drugs. Drugs without intrinsic sympathomimetic activity produce an 
initial reduction in cardiac output and a reflex-induced rise in peripheral resistance, 
generally with no net change in arterial pressure. In patients who respond with a 
reduction in blood pressure, peripheral resistance gradually returns to pretreatment 
values or less. Generally, persistently reduced cardiac output and possibly decreased 
peripheral resistance accounts for the reduction in arterial pressure. Drugs with intrinsic 
sympathomimetic activity produce lesser decreases in resting heart rate and cardiac 
output; the fall in arterial pressure correlates with a fall in vascular resistance below 
pretreatment levels, possibly because of stimulation of vascular α2 adrenergic receptors 
that mediate vasodilation. Drugs without intrinsic sympathomimetic activity produce an 
initial reduction in cardiac output and a reflex-induced rise in peripheral resistance, 
generally with no net change in arterial pressure. In patients who respond with a 
reduction in blood pressure, peripheral resistance gradually returns to pretreatment 
values or less. Generally, persistently reduced cardiac output and possibly decreased 
peripheral resistance accounts for the reduction in arterial pressure. Drugs with intrinsic 
sympathomimetic activity produce lesser decreases in resting heart rate and cardiac 
output; the fall in arterial pressure correlates with a fall in vascular resistance below 
pretreatment levels, possibly because of stimulation of vascular β2 adrenergic receptors 
that mediate vasodilatation. 
Propranolol is the proto type agent for class of β-adregernic blocking agents. 
Propranolol has equal affinity for β1 and β2 adrenergic receptors; thus, it is a 
nonselective β adrenergic receptor antagonist. Propranolol is a pure antagonist, lacks 
intrinsic sympathomimetic activity. For the treatment of hypertension and angina, the 
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initial oral dose of propranolol generally is 40 to 80 mg per day. The dose may then be 
titrated upward until the optimal response is obtained. For the treatment of angina, the 
dose may be increased at intervals of less than 1 week, as indicated clinically.  
Propranolol is also used to treat supraventricular arrhythmias/tachycardias, ventricular 
arrhythmias/tachycardias, premature ventricular contractions, digitalis-induced 
tachyarrhythmias, myocardial infarction, pheochromocytoma, and the prophylaxis of 
migraine. It also has been used for several off-label indications including parkinsonian 
tremors (sustained-release only), akathisia induced by antipsychotic drugs, variceal 
bleeding in portal hypertension, and generalized anxiety disorder. Propranolol may be 
administered intravenously for the management of life-threatening arrhythmias or to 
patients under anesthesia.21 Because all β adrenergic receptor antagonists are effective 
antihypertensive agents and (+)-propranolol, the inactive isomer that has little β-
adrenergic receptor blocking activity, has no effect on blood pressure, the 
antihypertensive therapeutic effect of these agents is undoubtedly related to receptor 
blockade.22 
Propranolol is highly lipophilic and is almost completely absorbed after oral 
administration. However, much of the drug is metabolized by the liver during its first 
passage through the portal circulation; on average, only about 25% reaches the 
systemic circulation. In addition, there is great inter individual variation in the 
presystemic clearance of propranolol by the liver; this contributes to enormous 
variability in plasma concentrations (approximately twentyfold) after oral 
administration of the drug and contributes to the wide range of doses in terms of 
clinical efficacy. A clinical disadvantage of propranolol is that multiple, increasing steps 
in drug dose may be required over time. The degree of hepatic extraction of 
propranolol declines as the dose is increased. The bioavailability of propranolol may be 
increased by the concomitant ingestion of food and during long-term administration of 
the drug. Propranolol has a large volume of distribution (4 liters/kg) and readily enters 
the CNS. Approximately 90% of the drug in the circulation is bound to plasma proteins. 
It is extensively metabolized, with most metabolites appearing in the urine. One 
product of hepatic metabolism is 4-hydroxypropranolol, which has some β adrenergic 
antagonist activity. 
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Analysis of the distribution of propranolol, its clearance by the liver, and its activity is 
complicated by the stereospecificity of these processes. The (-)-enantiomers of 
propranolol and other β blockers are the active forms of the drug. The (-)-enantiomer of 
propranolol appears to be cleared more slowly from the body than is the inactive 
enantiomer. The clearance of propranolol may vary with hepatic blood flow and liver 
disease and also may change during the administration of other drugs that affect 
hepatic metabolism. Monitoring of plasma concentrations of propranolol has found 
little application, since the clinical endpoints (reduction of blood pressure and heart 
rate) are readily determined. The relationships between the plasma concentrations of 
propranolol and its pharmacodynamic effects are complex; for example, despite its 
short half-life in plasma (about 4 hours), its antihypertensive effect is sufficiently long-
lived to permit administration twice daily. Some of the (-)-enantiomer of propranolol 
and other β blockers is taken up into sympathetic nerve endings and is released upon 
sympathetic nerve stimulation.23  
2.1.2.2 Adverse Effects of β-blockers 
Β-blockers should be avoided in patients with reactive airway disease (asthma) or with 
sinoatrial or atrioventricular (AV) nodal dysfunction or in combination with other drugs 
that inhibit AV conduction, such as verapamil. Patients with insulin-dependent diabetes 
also are better treated with other drugs. β Receptor antagonists without intrinsic 
sympathomimetic activity increase concentrations of triglycerides in plasma and lower 
those of HDL cholesterol without changing total cholesterol concentrations. β -
adrenergic blocking agents with intrinsic sympathomimetic activity have little or no 
effect on blood lipids or increase HDL cholesterol. The long-term consequences of these 
effects are unknown. Sudden discontinuation of some β adrenergic blockers can 
produce a withdrawal syndrome that is likely due to up-regulation of β receptors during 
blockade, causing enhanced tissue sensitivity to endogenous catecholamines; this can 
exacerbate the symptoms of coronary artery disease. The result, especially in active 
patients, can be rebound hypertension. Thus, β adrenergic blockers should not be 
discontinued abruptly except under close observation; dosage should be tapered over 
10 to 14 days prior to discontinuation. 
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2.1.2.3 Chemistry of β - blockers 
In medicinal chemistry, the chemist attempts to design and synthesize a medicine or a 
pharmaceutical agent which will benefit humanity. Recently, several clinical trials have 
demonstrated that beta-blockers remarkably reduced mortality in patients with 
moderate heart failure as well as improved the quality of life and sense of well-being by 
reducing hospitalizations and arrhythmias.24 β - Blockers are all structurally similar 
agents known as aryloxypropanolamines. This name originates from the presences of 
an –OCH2- group located between a substituted aromatic ring and an ethylamino side 
chain of pronethalol (1). The aromatic ring and substituents are the primary 
determinants of β antagonist selectivity. Propranolol (2), nadolol (3), timolol (4) and 
pindolol (5) are non-specific β blockers whereas para position substitutions on the 
aromatic rings of metoprolol (6), atenolol (7), esmolol (8), acebutolol (9) both confer β1 
antagonist selectivity.25  
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2.2  ALKYLAMINOHYDROXYPROPOXY SIDECHAIN DERIVATIVES 
The concept of alkyl aminohydroxypropoxy (10) side chain derivatives is understood by 
class of β – adrenergic blocking agents. Researchers who were studying the effects of 
aryl ring and aryl substitution in the molecule tried to modify the ethanolamine chain 
itself by inter alia, the introduction of linking group between aryl ring and ethanolamine 
chain. After lots of linking groups tried, the best linking group comes out to be 
oxymethylene. It is first analog, propranolol which is the most widely used β - blocker 
now and is 10 to 20 times potent than its parent compound pronethalol.26 Propranolol 
belongs to the group of β-blocking agents known as aryloxypropanolamines. Bulky 
aliphatic groups, such as the tert-butyl and isopropyl groups, are normally found on the 
amino function of the aryloxypropanolamine β-receptor antagonist. The configuration 
of the hydroxyl-bearing carbon of the aryloxypropanolamine side chain plays a critical 
role in the interaction of β-blocking agents with β receptors. The aryl group affect on 
pharmacokinetic parameter of the β-blockers. 
N
H
OH
O R1R/Ar
10  
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 2.3 THROMBO-EMBOLISM 
Thrombosis is the formation of a blood clot (thrombus) inside a blood vessel, 
obstructing the flow of blood through the circulatory system. When a blood vessel is 
injured, the body uses platelets and fibrin to form a blood clot to prevent blood loss. If 
the clotting is too severe and the clot breaks free, the traveling clot is now known as an 
embolus. Sometimes, part, or all, of a blood clot can come away from its original site 
and travel through the bloodstream. If this occurs, the clot can become lodged in 
another part of the body. This is known as an embolism. Thromboembolism is the 
combination of thrombosis and its main complication, embolism. When a thrombus 
occupies more than 75% of surface area of the lumen of an artery, blood flow to the 
tissue supplied is reduced enough to cause symptoms because of decreased oxygen 
(hypoxia) and accumulation of metabolic products like lactic acid. More than 90% 
obstruction can result in anoxia, the complete deprivation of oxygen, and infarction, a 
mode of cell death. The symptoms of a thromboembolism depend on the organ or 
blood vessel that has lost blood supply. Blood clots in an arm or leg may cause pain, 
swelling, and increased temperature in the affected area. A clot that travels to the lung 
is called a pulmonary embolus. This condition can cause: chest pain, shortness of 
breath, rapid heartbeat, known as tachycardia, fainting or death. If a blood clot is 
formed in the heart, it can travel to almost any organ in the body. This could cause a 
stroke, which is a type of damage to the brain from lack of blood circulation. In other 
cases, damage may be done to an arm or leg, or a heart attack or kidney damage may 
occur. Other areas of the body can also be affected. 
2.3.1  Antithrombic Treatment 
An antithrombotic is a drug which reduces thrombus formation. Different 
antithrombotic affect different processes:  
1. Antiplatelet drugs - limit the migration or aggregation of platelets.                                            
2. Thrombolytic drugs - act to dissolve clots after they have formed.                                          
3.     Anticoagulants - limit the ability of the blood to clot.   
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2.3.1.1  Antiplatelet Drugs 
An Antiplatelet drug (antiaggregant) is a member of a class of pharmaceuticals that 
decrease platelet aggregation27 and inhibit thrombus formation. The most important 
antiplatelet drugs are: (a) Cyclooxygenase inhibitors e.g. Aspirin (11) (b) Adenosine 
diphosphate (ADP) receptor inhibitors e.g. Clopidogrel (12), Prasugrel (13), Ticlopidine 
(Ticlid) (14) (c) Phosphodiesterase inhibitors e.g. Cilostazol (15) (d) Glycoprotein IIB/IIIA 
inhibitors e.g. Abciximab. 
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2.3.1.2 Thrombolytic Drugs 
Thrombolytic drugs are used to dissolve blood clots in a procedure termed 
thrombolysis. They limit the damage caused by the blockage of the blood vessel. 
Thrombolysis is used in myocardial infarction (heart attack), thromboembolic strokes, deep vein 
thrombosis and pulmonary embolism to clear a blocked artery and avoid permanent damage to 
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the perfused tissue. The thrombolytic drugs include: a) tissue plasminogen activator e.g. 
alteplase, reteplase, anisteplase, streptokinase, urokinase. 
2.3.1.3 Anticoagulants 
An anticoagulant is a substance that prevents coagulation; that is, it stops blood from clotting. 
Anticoagulants were introduced into medical practice more than three decades ago. 
Extensive use of these drugs in the prevention and treatment of thromboembolic 
disease has made them one of the most widely used classes of pharmacological agents. 
Anticoagulant drugs include:  
a) Heparin and derivative substances e.g. Low molecular weight heparin  
b) Vitamin K antagonists e.g. Warfarin  
2.3.1.3.1 Warfarin 
Warfarin and related 4-hydroxycoumarin-containing molecules decrease blood 
coagulation by inhibiting vitamin K epoxide reductase, an enzyme that recycles oxidized 
vitamin K to its reduced form after it has participated in the carboxylation of several 
blood coagulation proteins, mainly prothrombin and factor VII. For this reason, drugs in 
this class are also referred to as vitamin K antagonists.[2] When administered, these 
drugs do not anticoagulate blood immediately. Instead, onset of their effect requires 
about a day before clotting factors being normally made by the liver have time to 
naturally disappear in metabolism, and the duration of action of a single dose of 
racemic warfarin is 2 to 5 days. Under normal pharmacological therapy the drugs are 
administered to decrease the action of the clotting factors they affect by 30 to 50%.[3] 
Therapeutic doses of warfarin decrease by 30% to 50% the total amount of each 
vitamin K-dependent coagulation factor made by the liver; in addition, the secreted 
molecules are undercarboxylated, resulting in diminished biological activity (10% to 
40% of normal). Congenital deficiencies of the procoagulant proteins to these levels 
cause mild bleeding disorders. Oral anticoagulants have no effect on the activity of fully 
carboxylated molecules in the circulation. Thus, the time required for the activity of 
each factor in plasma to reach a new steady state after therapy is initiated or adjusted 
depends on its individual rate of clearance. The approximate half-lives (in hours) are as 
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follows: factor VII, 6; factor IX, 24; factor X, 36; factor II, 50; protein C, 8; and protein S, 
30. Because of the long half-lives of some of the coagulation factors, in particular factor 
II, the full antithrombotic effect of warfarin is not achieved for several days, even 
though the PT may be prolonged soon after administration due to the more rapid 
reduction of factors with a shorter half-life, in particular factor VII. There is no obvious 
selectivity of the effect of warfarin on any particular vitamin K-dependent coagulation 
factor, although the antithrombotic benefit and the hemorrhagic risk of therapy may be 
correlated with the functional level of prothrombin, and to a lesser extent, factor X.28 
 The usual adult dose of warfarin is 5 mg per day for 2 to 4 days, followed by 2 to 10 mg 
per day as indicated by measurements of the international normalized ratio (INR), a 
value derived from the patient's PT (see functional definition of INR in section on 
laboratory monitoring, below). A lower initial dose should be given to patients with an 
increased risk of bleeding, including the elderly. Warfarin usually is administered orally; 
age correlates with increased sensitivity to oral anticoagulants. Warfarin also can be 
given intravenously without modification of the dose. Intramuscular injection is not 
recommended because of the risk of hematoma formation.  
Warfarin is a synthetic derivative of dicoumarol, a 4-hydroxycoumarin-derived 
mycotoxin anticoagulant originally discovered in spoiled sweet clover-based animal 
feeds. Dicoumarol, in turn, is derived from coumarin, a sweet-smelling but coagulation-
inactive chemical found naturally in "sweet" clover (to which it gives its odor and name) 
and many other plants. The name warfarin stems from its discovery at the University of 
Wisconsin, incorporating the acronym for the organization which funded the key 
research (WARF, for Wisconsin Alumni Research Foundation) and the ending -arin, 
indicating its link with coumarin. 
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2.4 COUMARIN  
The story of the coumarin anticoagulants generally is traced back to the early 1920s, 
when the "sweet clover disease" showed up almost simultaneously in North Dakota and 
in Alberta, Canada. This new malady of cattle involving fatal bleeding was traced to 
stacks of sweet clover hay.29 Professor Link and his students at the Wisconsin 
Agriculture Experiment Station set out to identify the hemorrhagic agent in 1934 and 
first struggled with developing a reliable bioassay. After mass isolation of the active 
ingredients, its structure was diagnosed as 3, 3'- methylenebis-(4-hydroxycoumarin) 
(17). Thousands of synthetic equivalents were prepared in 1940. Since 1940, hundreds 
of 4-hydroxycoumarin-based compounds have been prepared and tested for 
anticoagulant activity, among these; warfarin quickly became the leader in clinical 
anticoagulant therapy. 
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 Although the coumarin anticoagulants have prolonged the lives of many patients during 
the first three decades of their therapeutic application (simultaneously promoting 
human welfare via pest control), our understanding of many basic aspects of these 
drugs is still meager. Only in recent years, detailed information on the metabolic fate of 
one of these compounds (warfarin) becomes known. No information has been 
presented for the other drugs of this group –not even for the analogs, although such 
studies would seem to be greatly simplified by following a protocol parallel to the 
warfarin work. Formerly, large quantities of coumarin were used in the food industry, 
mostly associated with vanillin, for flavouring chocolates, baked goods, and in cream 
soda-flavored beverages, but since 1954 its use as a direct food additive has been 
suspended in the United States.30 
                                                                                 Introduction 
 
Page 29 
 
2.4.1  Chemistry of Coumarin 
Structural formula:      
    
O O
  
Empirical formula:    C9H6O2                                                                                           
Relative molecular mass:  146.15 
Nomenclature of coumarin                                                                                                                                              
Chem. Abstract Name:  2H-1-Benzopyran-2-one                                                                            
IUPAC Systematic Name:  Coumarin                                                                                                              
Synonyms:    1,2-Benzopyrone 
Physical and chemical properties                                                                                                               
(a) Description:  Orthorhombic, rectangular plates; pleasant, fragrant odor resembling 
that of vanilla beans; burning taste                                                                                                                
(b)   Boiling-point: 301.7 °C                                                                                                                                   
(c)    Melting-point: 71 °C                                                                                                                                
(d)   Density: 0.935 g/cm3 at 20 °C                                                                                                                   
(e) Spectroscopy: Infrared (prism [1691]; grating [270]), ultraviolet [492], nuclear 
magnetic resonance (proton, [10407, V-225]; C-13 [242]) and mass spectral data have 
been reported                                                                                                                                                     
(f) Solubility: Slightly soluble in water (100 mg/L at 25 °C) and ethanol; very soluble  in  
chloroform,  diethyl  ether  and  pyridine                                                                                                 
(g)   Volatility: Vapour pressure, 0.13 kPa at 106 °C                                                                          
(h)   Octanol/water partition coefficient (P): log P, 1.39 (i) Conversion factor 1: mg/m3 
= 5.98 × ppm 
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Coumarin  has  a characteristic hay-like, sweet aromatic creamy odor with certain nutty 
shadings, much used in synthetic form as a fragrance chemical for various products like 
toothpastes,  antiperspirant  deodorants,  bath products, body lotions, face creams, 
fragrance creams, hair sprays, shampoos, shower gels and toilet soaps.  Coumarin has 
been used in detergents as a brightener or bleaching agent. It is used as an odor-
enhancer to achieve  a  long-lasting  effect  when  combined  with  natural  essential  
oils  such  as lavender, citrus, rosemary and oak moss. Coumarin is used in tobacco to 
enhance its natural aroma. It is also applied in large quantities to give pleasant aromas 
to house- hold materials and industrial products or to mask unpleasant odours.  
Coumarin is a widely occurring secondary metabolite that occurs naturally in several 
plant families and essential oils. Coumarins, the name of this chemical family is derived 
from Coumarouna  odorata   Aube   (Dipteryx   odorata) tonka beans ,  from which was 
isolated, for the first time, the simplest member of this class, coumarin itself. A broad 
spectrum of coumarin derivatives (present both in the free state and as glucosides) 
have also been found in many plants; to date at least 1300 have been identified, 
principally as secondary metabolites in green plants (Hoult 1996). Until the late 1890s, 
coumarin was obtained commercially only from natural sources by extraction from 
tonka beans. Synthetic methods of preparation and industrial manufacturing processes 
were developed starting principally from ortho-cresol (Raschig process), phenol 
(Pechmann reaction) and salicylaldehyde (Perkin reaction). Various methods can be 
used to obtain coumarin from each of these starting materials. In order to be suitable 
for perfumery uses, synthetic coumarin must be highly pure. Information available in 
1999 indicated that coumarin was manufactured by five companies in China, three 
companies each in Japan and the United States, two companies in France and one 
company each in Germany, Hong Kong and India. Coumarin is commercially available 
with a minimum purity of 99%.31 Coumarin is usually sold in the form of colorless shiny 
leaflets or rhombic crystals. 
Coumarin is an  anhydride of o-coumaric acid (2H-1-benzopyran-2-one)  having white, 
crystalline lactone, obtainable naturally from  several  plants,  such  as  tonka  bean,  
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lavender,  sweet  clover  grass,  strawberries,  and cinnamon,  or  produced  
synthetically  from  an  amino  acid,  phenylalanine.  Bio synthetically, coumarin  
nucleus (benzo-2-pyrone) is derived from cinnamicacid (phenylacrylic skeleton).  
Accordingly, 7th position of the hydroxy group attached to coumarin structure is 
important in biosynthesis pathway, i.e. Umbelliferone (7-hydroxy coumarin), esculetin 
(6,7-Dihydroxycoumarin), scopoletin (7-hydroxy-6-methoxycoumarin) are the 
widespread coumarins in nature. 
Table 2: Types and Examples of Coumarins 
32
 
Classification Features Examples 
Simple coumarins 
Hydroxylated, Alkylated, 
Alkoxylated on benzene 
ring 
7- Hydroxy Coumarin 
O O
HO
 
Furano coumarins 
5 membered furan ring 
attached on benzene ring 
Psoralen 
O O
O  
Pyranocoumarins 
Six membered pyrone 
ring attached on benzene 
ring 
Seselin 
O O
O
 
Pyrone Substituted 
coumarines 
Substitution on pyrone 
ring 
Warfarin 
O
OH CH2COCH3
O  
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Warfarin was synthesized by Ikawa in 1942 in the laboratory of Professor Link and the 
discovery of its high anticoagulant activity in rats, found extensive application as a 
rodenticide. Warfarin was introduced into clinical anticoagulant therapy in 1952. Since 
195S, sodium warfarin has been the leading anticoagulant in clinical practice. It is esti-
mated that about 85% of the oral anticoagulation in the United States is via 
sodiumwarfarin (Coumadin). Following the report of a hemorrhagic disorder in cattle 
that resulted from the ingestion of spoiled sweet clover silage, Campbell and Link, in 
1939, identified the hemorrhagic agent as bishydroxycoumarin (dicoumarol). In 1948, a 
more potent synthetic congener was introduced as an extremely effective rodenticide; 
the compound was named warfarin as an acronym derived from the name of the 
patent holder, Wisconsin Alumni Research Foundation. Warfarin's potential as a 
therapeutic anticoagulant was recognized but not widely accepted, partly due to fear of 
unacceptable toxicity. However, in 1951, an Army inductee uneventfully survived an 
attempted suicide with massive doses of a preparation of warfarin intended for rodent 
control. Since then, these anticoagulants have become a mainstay for prevention of 
thromboembolic disease.   
Numerous anticoagulants have been synthesized as derivatives of 4-hydroxycoumarin 
and of the related compound, indan-1,3-dione. Only the coumarin derivatives are 
widely used; the 4-hydroxycoumarin residue, with a nonpolar carbon substituent at the 
3 position, is the minimal structural requirement for activity. This carbon is 
asymmetrical in warfarin (and in phenprocoumon and acenocoumarol). The 
enantiomers differ in anticoagulant potency, metabolism, elimination, and interactions 
with other drugs. Commercial preparations of these anticoagulants are racemic 
mixtures. No advantage of administering a single enantiomer has been established. The 
oral anticoagulants are antagonists of vitamin K (see section on vitamin K, below). 
Coagulation factors II, VII, IX, and X and the anticoagulant proteins C and S are 
synthesized mainly in the liver and are biologically inactive unless 9 to 13 of the amino-
terminal glutamate residues are carboxylated to form the Ca2+-binding g-
carboxyglutamate (Gla) residues. This reaction of the descarboxy precursor protein 
requires carbon dioxide, molecular oxygen, and reduced vitamin K, and is catalyzed by 
g-glutamyl carboxylase in the rough endoplasmic reticulum. Carboxylation is directly 
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coupled to the oxidation of vitamin K to its corresponding epoxide.  
 
Coumarin analogue, dicumarol33 and its synthetic derivative warfarin sodium having an 
anticoagulant nature are used for the treatment of a variety of cancers. They act by 
disorganizing the mitotic spindle microtubules in cells, leading to the random 
distribution of the chromosomes at metaphase.  Because  of  its low toxicity  and 
simple  chemical  structure,  there  is   potential  interest  to explore combinations 
random antimitotic  coumarins  with  other chemotherapeutic  agents  to  improve  
efficacy  and  lower toxicity of anti cancer drugs. Coumarin anticoagulants inhibit the 
pathway involving tissue factor and factor VIIa. Tissue factor VIIa appears to be a major 
factor in the regulation of angiogenic growth properties of tumor cells.34 
Coumarin has no anticoagulant activity; it is transformed into the natural anticoagulant 
dicoumarol by a number of species of fungi. This occurs as the result of the production 
of 4-hydroxycoumarin, then further (in the presence of naturally occurring 
formaldehyde) into the actual anticoagulant dicoumarol, a fermentation product and 
mycotoxin. This substance was responsible for the bleeding disease known historically 
as "sweet clover disease" in cattle eating moldy sweet clover silage. Coumarin 
possesses immunomodulatory and direct antitumor activity. Coumarin has been 
recommended for treatment of a number of clinical conditions, including high protein 
oedema and brucellosis. It is currently undergoing clinical trials for treatment of 
lymphoedema following breast cancer treatment and in treatment of lung and kidney 
cancer and of melanoma alone or in combination with cimetidine. It has also been used 
for preven- tion of dental caries. Coumarin and some of its derivatives have been tested 
for treatment of schizophrenia, microcirculation disorders and angiopathic ulcers, and 
also for treatment of high protein oedemas in animals.  
Coumarin derivatives are used as therapeutic anticoagulants and as rodenticides by 
causing fatal hemorrhage. Because the range between efficient therapy and undue 
hemorrhagic risk may vary greatly from one patient to another, the need for carefully 
individualized treatment and frequent observations has long been stressed. However, a 
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summary of recent research findings, along with certain principles, may offer possible 
explanations for responsiveness to make highly efficient lead with fewer side effects to 
resist both, coagulopathy as well as hypertension. The primary aim of this present work 
is to study pharmacological and synthetic aspects of the coumarin ring structure 
especially its combined analogues profile as an anti coagulant and anti hypertensive 
property.  
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2.5 CONCURRENT USE OF ANTIHYPERTENSIVE AND ANTICOAGULANT 
DRUGS  
The main complications of hypertension, i.e. coronary heart disease, ischemic strokes 
and peripheral vascular disease (PVD), are usually related to thrombosis. Increasing 
evidence also suggests that hypertension fulfils the components of Virchow's triad, thus 
conferring a prothrombotic or hypercoagulable state, as evident by abnormalities of 
haemostasis, platelets and endothelial function. It therefore seems plausible that use of 
antithrombotic therapy may help prevent these thrombosis-related complications of 
hypertension. Indeed, hypertensive patients with an estimated 10-year CHD risk > or = 
15% will have their cardiovascular risk reduced by 25% using antihypertensive 
treatment, but the addition of aspirin further reduces major cardiovascular events by 
15%. Recent guidelines recommend the use of aspirin 75 mg daily for hypertensive 
patients who have no contraindication to aspirin.35 Further, although systemic (arterial) 
elevations in blood pressure result in high intravascular pressure, the main 
complications of elevated blood pressure, coronary heart disease (CHD) events, 
ischemic stroke and peripheral vascular disease (PVD), are related to thrombosis. The 
association between elevated blood pressure and risk for stroke and CHD has a linear 
relationship, with increasing risk for higher blood pressures.36 In addition it should be 
recognized that some of the complications related to elevated blood pressure, heart 
failure or atrial fibrillation, are themselves associated with thromboembolism.37 
Increasing evidence also points towards a prothrombic or hypercoagulable state 
conferred by the presence of elevated blood pressure, as evident by abnormalities of 
coagulation, platelets and endothelial function in such patients.38-39 
It therefore seems plausible that use of antithrombotic therapy may be of particular 
benefit in preventing the thrombosis-related complications of elevated blood 
pressure.40 The antithrombotic agent, acetylsalicylic acid (ASA), is established as an 
effective agent for secondary prevention in patients with proven occlusive vascular 
disease.41 However, it is not recommended for primary prevention and it is unclear 
whether it has a role in patients with an increased risk of thrombotic complications such 
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as those with elevated blood pressure. Warfarin has also been found to be useful as 
thromboprophylaxis in patients with elevated blood pressure and atrial fibrillation 
(Segal 2001, SPAF II Study 1994); however, if blood pressures remain uncontrolled, such 
therapy carries significant risk, especially from intracranial haemorrhage. 
Thus, since hypertension and thrombo-embolism are intricately involved in 
pathophysiological changes and progression of cardio-vascular diseases; 
antihypertensive drugs like propranolol and anticoagulant drugs like warfarin are 
frequently, combined in management of some types of hypertension. However, in 
clinical practice, it has been noted that prescribing, one drug with two different 
activities, improves patient compliance to the treatment instead of two drugs with two 
different activities resulting in better clinical outcome. Therefore, in the present project, 
we attempted to synthesize a single drug molecule with antihypertensive activity of 
propranolol and anticoagulant activity of Warfarin (Coumadin).  
To achieve this, we attached alkylaminohydroxypropoxy side chain (responsible for 
antihypertensive activity of propranolol) to 4-Hydroxy coumarin nucleus (responsible 
for anticoagulant activity of warfarin). Several resulting molecules were then, subjected 
to pharmacological evaluation, for both types of activities, to assess structure activity 
relationship and to ascertain the lead molecule.   
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3. OBJECTIVES OF THE PROJECT 
Warfarin contains coumarin skeleton and propranolol contains isopropylamino-2-
hydroxypropoxy side chain. Our aim was to synthesize antihypertensive agents with 
anticoagulant activity. Hence, the objectives of the present project were - 
 To synthesize a series of drug molecules having coumarin skeleton with 
alkylamino-2-hydroxypropoxy side chain. 
 To subject the series of synthesized molecules to pharmacological evaluation 
for antihypertensive and anticoagulant activity so as to assess the structure 
activity relationship and to ascertain the lead molecule.   
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4. LITERATURE REVIEW 
Epidemiologists in India and international agencies, such as  the World Health 
Organization (WHO), have been sounding an alarm on the rapidly rising burdens of 
cardiovascular diseases (CVD) for the past 15 years. Cardiovascular diseases include 
hypertension, hyperlipidemia, heart failure, angina pectoris, arrhythmia etc. The 
reported prevalence of coronary heart disease (CHD) in adult surveys has risen 4-fold 
over the last 40 years (to a present level of around 10%), and even in rural areas the 
prevalence has doubled over the past 30 years (to a present level of around 4%). 
Cardiovascular disease is now the leading cause of death, accounting for 29% of all 
deaths in 2005, according to the WHO.2 India, already the diabetes capital of the 
world with 32 million persons with diabetes, is projected to have 69.8 million in 
2025. The count of "hypertensive" individuals is expected to rise from 118 million in 
2000 to 214 million in 2025.  
4.1 Antihypertensive Drugs 
Hypertension is a multi factorial disease frequently associated with other 
cardiovascular problems. None of the antihypertensive drugs available can cure all 
cases of hypertension. Use of drugs acting on the adrenergic system, diuretics, 
calcium antagonists, nitro-vasodilators and so on, have not yet been abandoned, 
while new compounds are still being developed today.42 
Van zwieten and his colleague concentrate on a considerable effort in 
neuropharmacological research have been invested in an attempt to localize the 
precise anatomical position of central α-adrenoceptors. However, localization in full 
detail has not been possible yet, owing to limitations of experimental methods. 
Central α-adrenoceptors are likely to be located within the brain stem.43 
Mancia et al. (2000) worked on ACE inhibitors. Recent studies revealed that in 
diabetic hypertensive patients, administration of angiotensin-converting enzyme 
(ACE)-inhibitors or calcium antagonists can effectively lower blood pressure and 
prevent diabetes-related cardiovascular complications with no adverse metabolic 
effects.44 Ishi and her colleague conclude that the systemic administration of 
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cimetidine with topical ocular timolol increases the degree of β blockade, resulting in 
a reduction of resting heart rate, intraocular pressure, and exercise tolerance.45 
Prakash et al. (2000) worked on metoprolol and proved that it is effective in chronic 
heart failure. It has been shown in randomized trials to be associated with a striking 
reduction in all-cause mortality and hospitalization for worsening heart failure and a 
modest reduction in all-cause hospitalization.47 Ferdinand and his colleagues worked 
in high-risk patients, including those with diabetes, renal insufficiency, left 
ventricular dysfunction, and atherosclerosis, and conclude that ACE inhibitors may 
have specific benefit in reducing cardiovascular morbidity and mortality.48 
Same time Mc Gavin et al. (2002) proved that bisoprolol is a highly selective β1 
receptor antagonist but it does not have intrinsic sympathomimetic or membrane-
stabilizing activity.49 To treat hypertension and decrease mortality, Elly and his 
colleague worked on effect of exercise on heart. They conclude that regular exercise 
improves blood flow and helps to reduce the resting heart rate and blood pressure.50 
Kumar et al. (2011) investigated a new rout of administration of metoprolol to 
achieve sustained drug release kinetics and form oral dosage form.51 
The hemodynamic consequences of long-term treatment with antihypertensive 
agents provide a rationale for potential complementary effects of concurrent 
therapy with two or more drugs. The simultaneous use of drugs with similar 
mechanisms of action and hemodynamic effects often produces little additional 
benefit. However, concurrent use of drugs from different classes is a strategy for 
achieving effective control of blood pressure while minimizing dose-related adverse 
effects.46 
4.2 β-BLOCKERS 
4.2.1 Pharmacological Aspects of Β-Blockers and Side Chain  
Hieble et al. synthesized a series of compounds which are derivative of 
alkylaminohydroxypropoxy and hydroxyl substituted on aromatic ring (17). 52 Powell 
and Slater described the activity of dichloroisoproterenol (18) and it was the first β 
blocker reported in 1958.53 Nakagawa et al. (1971) synthesized antiarrhythmic 5-(3-
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alkylamino-2-hydroxypropoxy)-8-nitro-3,4-dihydrocarbostyrils (19) derivatives.54 
After getting success, Nakagawa and his colleague (1976) synthesized antiarrhythmic 
and antianginal compounds having 5-(3-Alkylamino-2-hydroxy)propoxy side chain of 
3,4-dihydrocarbostyrils derivative (20). They also performed activity of synthesized 
5-(3-Alkylamino-2-hydroxy) propoxy-8-hydroxy-3,4-dihydrocarbostyrils (21) 
derivatives and proved antihypertensive activity.55 Black et al. performed activity of 
many compounds, they found that pronethalol (22) and propranolol (23) has β 
antagonistic activity.56 Kaiser et al. (1977) reported that –OCH2– group is responsible 
for binding at β-receptor site for agonistic or antagonistic activity.57 Then research 
was carried out for analyze other parameters like metabolism and excretion of drug 
through body. Riddell and his colleagues proved that the aryl group affects the 
absorption, excretion and metabolism of the β blockers.58  
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Discovery of propranolol cause increase research of cardiovascular system. 
Researcher modified aromatic skeleton and performed activity of synthesized 
compounds. Binder et al. (1982) synthesized 3 substituted thiophene derivatives (24) 
and performed antiarrythmic activity induced by calcium chloride in mice.59 Chalina 
et al. (1987) synthesized 5,8 bis(3-Alkylamino-2-hydroxy)propoxy-1,4-
dihydronaphthalene (25) and pharmacological screening showed hypotensive and β-
adrenoceptor blocking activities, as well as low toxicity.60 Cai et al. (1990) 
synthesized 3-[4-[(3-alkylamino-2-hydroxy) propoxy] phenyl (benzyl)]-substituted-
4(3H)-quinazolinones (26) derivatves and showed increase the tolerance of mice to 
hypoxia.61 Lots of research works on alkylaminohydroxypropoxy side chain prove 
that it plays important role for β-blocking activity. Racanska et al. (1990) tried to find 
relationship between the chemical structure and pharmacological activity of some 
newly synthesized alkylesters of 4-[(2-hydroxy-3-alkylamino) 
propoxy]phenylcarbamic acids derivatives (27). They conclude that 4-substituted 
derivatives of aryloxypropanolamines had antiisoprenaline (beta-adrenolytic) and 
local anesthetic (membrane stabilizing) activity.62 Discovery of other 
antihypertensive agents and minimize their drawbacks was excellence research 
during that time.  
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Ondriasova et al. (1992) compared the potency of five potential β-adrenoceptor 
blocking drugs like  alkylesters of 4-[(2-hydroxy-3-alkylamino) 
propoxy]phenylcarbamic acid derivative and eight calcium channel blockers like 
nifedipine, nimodipine, niludipine, nitrendipine, verapamil etc. to inhibit platelet 
aggregation and to perturb liposomal membranes prepared from platelet lipids.63 
4.2.2 Chemical Aspects of β-Blockers and Side Chain  
Turner et al. (1968) synthesized 4(5,6, and 7)-(3-Alkylamino-2-hydroxy-1-propoxy) 
benzofurans (28) and indoles from mixture of  4-hydroxybenzofuran,  
epichlorohydrin and piperidine. Further reaction was amination to produce final 
products.64 Troxler et al. (1971) synthesized 4-[2-Hydroxy-3-(alkylamino)propoxy]-2-
(methoxymethyl)indoles (29) by treating 4-hydroxy-2-(methoxymethyl)indole with 
epichlorohydrin in aqueous dioxane in the presence of sodiumhydroxide. 
Synthesized compounds possessed β-blockling and antiarrithmic activity.65 Sato et al. 
(1972) synthesized twenty-three tropone derivatives from methoxytropones, p-
aminophenol followed by reaction with epibromohydrin and followed by amination. 
Final compounds showed adrenergic blocking, hypotensive, and vasodilating 
activity.66  
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Ahmed et al. (1998) performed reaction of 4-hydroxyquinaldine/6-bromo-4-
hydroxyquinaldine/6-fluoro-4-hydroxyquinaldine with epichlorohydrin followed by 
amination to form 4-(3-alkylamino-2-hydroxy-1-propoxy)quinaldines (30) and 6-
haloquinaldines derivatives. Synthesized compounds were evaluated for their 
antihypertensive activity and beta blocking activity against chronotropic response to 
adrenaline. The iso-propyl and tert-butyl analogs showed marked decrease in blood 
pressure, the iso-propyl analogs were more potent than propranolol. All synthesized 
compounds exhibited marked decrease in heart rate, cardiac output and force of 
contraction. This work was continued for multiple pharmacological activities rather 
than single antihypertensive activity.67 Ahmed et al. (1998) synthesized 6-hydroxy 3-
substituted, 6-(alkylamino(hydroxy)propoxy)-2H-1,2,4-benzothiadiazine-1,1-dioxide-
7-sulfonamides. They have synthesized 6-Hydroxy-3-(substituted)-7-sulfamoyl-3,4-
dihydro-1,2,4-benzothiadiazine 1,1-dioxides by condensing 3-aminophenol-4,6-
disulfonamide with different aldehydes. 6-(3-Alkylamino-2-hydroxypropoxy)-7-
sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxides were obtained by reacting 6-
hydroxy-7-sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide with epichlorohydrin 
followed by addition of different alkylamines. These compounds being a hybrid of 
benzothiadiazine (diuretics) and aryloxypropoxyamines (β-adrenergic blockers) are 
expected to have both these properties and may be useful as better hypotensive 
compounds.68 
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4.3 ANTICOAGULANTS 
4.3.1 Pharmacological Aspects of Anticoagulants 
The story of the coumarin anticoagulants generally is traced back to the early 1920. 
When the "sweet clover disease" showed up in North Dakota, Alberta and Canada, 
many scientist made in surprise for increase bleeding in cattle by sweet clover plant. 
Vogel et al. (1920) showed that coumarin is a widely occurring secondary metabolite 
that occurs naturally in several plant families. Coumarin name of this chemical family 
is derived from Coumarouna  odorata   Aube   (Dipteryx   odorata) tonka beans,  from 
which coumarin was isolated first time.69 Professor Link and his students (1934) 
developed reliable bioassay method of anticoagulation at the Wisconsin Agriculture 
Experiment Station. Campbell and Link (1939) ingested spoiled sweet clover silage in 
cattle and produced hemorrhagic disorder. Finally they identified the hemorrhagic 
agent as bishydroxycoumarin derivative and named as dicumarol (16).  After 
discovery of dicumarol many scientists worked on coumarin derivatives to discover 
other anticoagulant agents. Ikawa and his colleague (1942) synthesized warfarin (15) 
in the laboratory of Professor Link and proved its high anticoagulant activity in rats, 
At that time it’s extensive application found as a rodenticide rather than 
anticoagulant. Warfarin was introduced into clinical anticoagulant therapy in 1952.70 
Shepard et al. (1944) studied the effect of synthetic vitamin K on the 
prothrombinopenia induced by salicylate in man. The prothrombinopenia resulting 
from dicumarol, which occurs only in vivo and after a certain latent period, due to 
the degradation of the dicumarol to 2 moles of salicylic acid. The same effect is 
obtained when salicylates are administered. It is, therefore, essential to determine 
the prothrombin level when salicylate therapy is used.71 Hais et al. (1951) worked on 
degradation of 4-hydroxycoumarin by using paper chromatography in urine and 
blood. . Ammonia-water-butanol or octanol system was used for the detection and 
identification of pelentan, dicoumarol and some of their degradation products in 
blood and urine.72  
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After successive discovery of warfarin as anticoagulant, scientist tried to found new 
applications of coumarin. Lacharme et al. (1952) worked on derivatives of 4-
hydroxycoumarin as inhibitors of germination and growth of plants. So, they gave 
new direction to agriculture field by performed above research.73 It was the time 
where parallel research was going in both medical and agricultural field. Martius et 
al. (1953) worked to discover mechanism of action of dicumarols and related 
compounds. 3,3'-Methylenebis (4-hydroxycoumarin)  and related compounds, they 
proved that compounds inhibit aerobic phosphorylation in mitochondria of rat.74  
Henrik  et al. (1954) worked to determine levels of vitamin K1 in blood and various 
organs of chicks and rats after administration of massive doses of K1. In chicks a 
massive dose of vitamin K1 injected intravenously (in colloidal suspension prepared 
with the aid of Tween 80) disappeared gradually from the blood stream and was 
deposited in the liver, spleen, and lungs. None was found in the bile. They proved 
that massive doses of given intravenously accumulated in the liver and spleen in rats. 
Only small amounts were found in the lungs and kidneys on the day after injection. 
After 28 days about 11 % of the dose was still present in liver and spleen.75  
Hellemans et al. (1963) determined the survival time of prothrombin and factors VII, 
IX and X after completely synthesis blocking doses of coumarin derivatives. The 
synthesis of prothrombin and of factors VII, IX, and X in dogs was completely blocked 
with 3-(1-phenylpropyl)-4-hydroxycoumarin (32), bis(4-hydroxy-3-coumarinyl)ethyl 
acetate (33), or 3-(α-acetonyl-p-nitrobenzyl)-4-hydroxycoumarin (34). They 
concluded that the half-lives of prothrombin, 41.0; cloting factor VII, 6.2; IX, 13.9; 
and X, 16.5 hrs.76 Giacomello et al. (1965) studied SAR of cholramphenicol they 
conclude that -COCHCl2 group is essential for antibacterial effect. So they 
synthesized dichloroacetic acid derivatives of coumarin and performed antibacterial 
activity of synthesized compounds.77   
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Rowe et al. (1967) studied the effect of sex and age on the response to warfarin in a 
noninbred strain of mice. They observed that marked sex difference in susceptibility 
to warfarin was found in 6-months old gray mice, males being more susceptible than 
females. No sex difference was found in young mice which were 6-weeks old.78 
Ichikawa et al. (1969) reported antibacterial activity of 3-substituted-7-amino-4-
hydroxy-coumarin derivatives (35).79 
Perone et al. (1972) survey that large quantities of coumarin were used in the food 
industry, mostly associated with vanillin, for flavoring chocolates, baked goods, and 
in cream soda-flavoured beverages.80 
Olson et al. (1975) studied on mode of action of vitamin K in regulating prothrombin 
synthesis. They developed hypothetical model in which vitamin K acts to regulate the 
biosynthesis of prothrombin and other vitamin K dependent clotting proteins at the 
ribosomal level are presented. The model provides a regulatory protein which binds 
vitamin K and the 4-hydroxy-coumarin drugs at separate sites and associates with 
both the 60S and 40S particle to ribosome and has a recognition site for the 
prothrombin messenger RNA which is attached to the 40S subunit of the ribosome.81 
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In U.S. Beriger reported insecticidal activity of synthesized active 3-N-(4-
trifluoromethylphenyl) carbamoyl-4-hydroxycoumarin (36) in 1975.  Ritschel et al. 
(1977) studied the pharmacokinetics of coumarin and its 7-hydroxy-metabolites 
upon intravenous and peroral administration of coumarin in man. They conclude 
that glucuronide conjugation is more preferred path for excretion.82 
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Sekiya et al. (1982) studied the effects of coumarin and its derivatives on rat platelet 
lipoxygenase and cyclooxygenase activities. Esculetin (37) was found to inhibit the 
lipoxygenase more strongly than the cyclooxygenase; its IC50 was 0.65 mM for 
platelet lipoxygenase and 0.45 mM for platelet cyclooxygenase. Esculin (the 6-
glucoside of esculetin) and umbelliferone (38) also selectively inhibited the 
lipoxygenase, though less strongly (IC50 = 290 and 500 mM, respectively). 4-
Hydroxycoumarin and coumarin had no inhibitory effect on either enzyme at 
concentrations up to 1 mM. The mechanism of the lipoxygenase inhibition by 
esculetin was non-competitive.83  
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Marshall et al. (1987) stated that coumarin has been recommended for treatment of 
a number of clinical conditions, including high protein edema and brucellosis. It is 
currently undergoing clinical trials for treatment of lymphoedema following breast 
cancer treatment and in treatment of lung and kidney cancer and of melanoma 
alone or in combination with cimetidine.84-90  
Chahinian (1989) proved anticancer activity of coumarin derivatives. They also 
proved their mechanism of action and conclude that they act by disorganizing the 
mitotic spindle microtubules in cells, leading to the random distribution of 
chromosomes at metaphase. Because of their low toxicity and simple chemical 
structure, there is potential interest to explore combination of antimitotic coumarins 
with other chemotherapeutic agents to improve efficacy and lower toxicity of 
anticancer drugs.91    
Egan et al. (1990) reported use of coumarin. They found that it is used as  odour-
enhancer to achieve  a  long-lasting  effect  when  combined  with  natural  essential  
oils  such  as lavender, citrus, rosemary and oak moss. Coumarin is used in tobacco 
to enhance its natural aroma. It is also applied in large quantities to give pleasant 
aromas to house - hold materials and industrial products or to mask unpleasant 
odours.92 Myszka et al. (1991) discovered fatty acid-binding protein (FABP) as a 
warfarin receptor in rat liver by photo affinity labeling method. They conclude that 
the high concentration of FABP was a major hepatic receptor responsible for the 
uptake and/or transport of various oral 4-hydroxycoumarin in liver.93 
Lake et al. (1993) first time proved hepatotoxicity of coumarin by oxidase enzyme 
inducers in the rat, and therefore many scientists worked on drawback of coumarin 
which is widely used as flavoring agent in food industries. Finally, the use of 
coumarin as direct food additive has been suspended in the United States.94 Further 
work was continued by Marshall et al. (1994). They reported that coumarin and 7-
hydroxycoumarin have immunomodulatory and antitumor activity.95 Chang et al. 
(1995) worked on esculetin, umbelliferone and 7-hydroxy-4-methyl coumarin and 
proved that all are strong xanthine oxidase inhibitors with IC50=20.91, 43.65 and 
96.70 mM respectively.96  
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Mileti et al. (1995) tried to form sustain release drug delivery system of Coumadin to 
decrease its severe side effects such as excessive hemorrhage and necrosis. They 
decreased the dosage of Coumadin by maintaining an effective threshold level of the 
drug using a hydroxyapatite ceramic drug delivery system.84-97 During this era, many 
scientists worked to prove other uses of coumarin above its highly severe side 
effects.  Galabov et al. (1996) found antiviral activity of esculetin. They showed that 
ten samples exhibited a marked inhibitory effect on Newcastle disease virus 
replication in cell cultures. Antiviral activity was proved on different species of virus 
like, picorna, orthomyxo, paramyxo, and herpes families.98  
Hoult et al. (1996) stated that many coumarin derivatives have been found in 
varieties of plants; to date more than 1300 green plants have been identified, 
principally as secondary plant metabolite.99 Botanical sources of coumarin are widely 
distributed in nature, which pull many scientists to take effort to prove its different 
pharmacological activity. Weber et al. (1998) reported antitumor activity of 
coumarin, 7-hydroxy-coumarin and its glucuronide in several human tumor cell lines. 
Both compounds inhibited cell proliferation of a gastric carcinoma cell line, a colon-
carcinoma cell line, a hepatoma-derived cell line and a lymphoblastic cell line.100 
Furthermore investigation on anti tumor activity is carried out by Mousa et al. 
(2000). They reported effect of coumarin on tissue factor VIIa, to be a major factor in 
the regulation of angiogenic growth properties of tumor cells.101 
Zaton et al. (2000) studied on binding of drugs to human serum albumin and 
determined drug distribution through systemic circulation. They found that 
structural features of 4-hydroxy-coumarin, 3-acetylcoumarin, coumarin, 
benzylthiouracil, propyluracil, thiouracil, chromone and chromanol are very similar 
to warfarin, propylthiouracil and cromoglycate. Because of structural similarity, 
these compounds were competitively displaced by warfarin at their primary binding 
sites on seroalbumin.102 Structural similarities and protein binding sites are new area 
of interest to found more toxic effects of coumarins and its derivatives. Parallel to 
this, Masamoto et al. (2001) investigated contact sensitization of 11 simple 
coumarins. Esculetin, 4-methylesculetin, and daphnetin were found to be strong 
sensitizers, and 4-hydroxy-coumarin to be a moderate sensitizer. The results suggest 
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that the introduction of hydroxy group, especially adjacent substitution at the 6, 7, 
and 8 positions of the coumarin ring with two hydroxy groups, may play an 
important role in exhibiting the contact sensitization activity. The cross-reactivity 
was observed between esculetin and 4-methylesculetin, esculin or isoscopoletin, and 
also between daphnetin and 4-methylumbelliferone or umbelliferone. It is 
interesting to note that guinea pigs, which had a weak sensitivity to umbelliferone, 
showed a strong cross-reactivity to daphnetin, while those, which had a weak 
sensitivity to daphnetin, showed a weak cross-reactivity to umbelliferone. It is 
assumed that a skin-protein conjugation at 5 or 6 positions of the coumarin ring is 
important to elicit the cross-reactivity of esculetin or daphnetin groups.103  
Chen et al. (2001) worked on coumarin group of antibiotics, such as novobiocin,  
coumermycin A1 and clorobiocin; those are potent inhibitors of DNA gyrase. They 
isolated these antibiotics from various streptomyces species and all possess a 3-
amino-4-hydroxy-coumarin moiety as their structural core. They conclude that the 
coumarin moiety was derived from L-tyrosine, probably via a β-hydroxy-tyrosine 
intermediate.104 Coumarine derivatives were extracted from different bacterial 
species. Sun et al. (2002) extracted 6-methoxy-7-hydroxycoumarin, β-sitosterol and 
5,7-dihydroxycoumarinI  from Morus alba. All structures were confirmed by by EI-
MS, IR, 1H NMR, UV analytical techniques. They determined anti asthmatic and anti 
diuretic activity of 6-methoxy-7-hydroxycoumarin.105 
Kamat et al. (2004) discovered the mechanism of interaction of four coumarin 
derivatives with bovine serum albumin using spectrofluorometric technique. It was 
concluded that the coumarin ring plays major role in interaction. Stern-Volmer plots 
and parachor values of coumarin derivatives explain the quenching mechanism.106 
Coumarin derivatives became the centre of interest for researchers for its anti tumor 
activity. Mazumder et al. (2004) showed promising antitumor activity of 3-hydroxy 
coumarin. Treatment with it prolonged the life span of mice as well as decreased 
their tumor volume and viable ascitic cell count. All the tested complexes exhibited 
mild to moderate antibacterial activity.107 
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Ghate et al. (2005) synthesized coumarinyl ethers having chromone, benzofuranyl 
and 4-hydroxy coumarins and tested them for analgesic and anti-inflammatory 
activity in rat. These newly synthesized compounds were found to produce less 
toxicity and less ulcerogenic activity.108 Different isolation methods to collect 
coumarin derivatives were being established. First time Yuan et al. (2005) isolated 6-
methoxyl-7-hydroxyl coumarin and 7-hydroxyl coumarin from roots of Ipomoea 
batatas Lam. variety Simon.109 Different synthetic methods were also produced to 
get various coumarin derivatives. Druzgala et al. (2005) prepared 3-benzyl-4-
hydroxy-coumarin derivatives as inhibitors of vitamin K epoxide reductase and 
posses anticoagulant activity. The activity (39, 40) was evaluated using cow liver 
microsomes.110 
Kontogiorgis et al. (2005) stated the anti inflammatory and antioxidant activity of 
novel coumarin derivatives. Some of them were found in vitro to inhibit lipid 
peroxidase and strongly scavenging superoxide radicals. Compd. 3 was found as a 
potent inhibitor of cyclooxygenase-1 and the yeast-induced rat paw edema. It was 
tested against adjuvant-induced arthritis and found to significantly protect the rats 
from it.111 More insight into pharmacological uses of coumarin and its derivatives 
was continued by researchers. Anamik et al. (2005) synthesized series 4-hydroxy 
derivatives and screened them in vitro for anti-HIV activity against HIV-1(IIIB) and 
HIV-2(ROD) virus strains. Compound (41) was found to be the most active.112  
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Coumarin got attention as an antifungal activity by Brooker et al. (2005). They 
synthesized halogenated (brominated, chlorinated, iodinated) coumarins and 
evaluated for antifungal activity against soil-borne plant pathogenic fungi (against 
Macrophomina phaseolina, Pythium spp., Phytophthora spp.) in soybean seed 
germination and in early development. Halogenated coumarin compounds have 
higher antifungal activity as 4-hydroxy-coumarin alone. Halogenated coumarins and 
4-hydroxy-coumarin showed 100% fungal inhibition for 21 days. Phytotoxicity tests 
were negative.113 
Cheng et al. (2005) discovered a novel application of coumarin compounds in 
preparing medicine for inducing directional differentiation of neural stem cell by 
treating demyelination or spinal cord injury.114 There were a number of reports that 
natural and synthetic coumarin derivatives posse’s antimicrobial activity.  Kulkarni et 
al. (2009) worked on in-vitro antimicrobial studies of Co(II), Ni(II), and Cu(II) 
complexes with Schiff bases of formyl coumarin derivatives. The Schiff bases and 
their complexes were screened for antibacterial (Escherichia coli, Staphylococcus 
aureus, Pseudomonas aeruginosa, and Salmonella typhii) and antifungal (Aspergillus 
niger, Aspergillus flavus, and Cladosporium) activities by Minimum Inhibitory 
Concentration (MIC) method. The redox behavior of the complexes was studied 
using cyclic voltammetry.115 
Bhattacharyya et al. (2009) found that isolated Scopoletin from Gelsemium 
sempervirens (Fam: Loganiaceae) has been reported to have anti-cancer potentials. 
So their colleague tried to synthesize 4-Methyl-7 hydroxy coumarin from resorcinol. 
They screened synthetic compounds for anti-cancer potentials and has been 
evaluated in vivo on DMBA (7,12-Dimethylbenz[a]anthracene) induced skin cancer in 
mice by analyzing results of several cytogenetic endpoints, Comet assay, and 
fluorescence activated cell sorting.116  
Yousef et al. (2010) prepared 4-hydroxy coumarin-3-thiocarbohydrazon by the 
reaction of 4-hydroxy coumarin with dithiocarbohydrazide in molar ratio 1:1, and 
performed some biochemical parameters and histological studies in serum, liver and 
kidney of rats. They observed the effect of Aspergillus niger and Candida albicans on 
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the radial growth. The results of this study prove that the complex at low dose has a 
better effect than the complex at high dose and the ligand at both high and low 
doses has no effect on the biochemical analysis in serum, liver, kidney tissues and 
histological examination in rats.117  
Vukovic et al. (2010) worked on synthesis and antioxidant properties of novel imino 
and amino derivatives of 4-hydroxy coumarins (42, 43). Series of imino and amino 
derivatives of 4-hydroxy coumarins were synthesized via conventional and 
microwave promoted procedure and evaluated for antioxidant potential through 
different in vitro models such as free radical scavenging activity, linoleic acid 
emulsion model system, reducing power assay and phosphomolybdenum method. 
All prepared compounds possess good antioxidant activity and among them p-nitro-
Ph derivative possesses radical scavenging activity which is comparable to BHT, while 
the best reducing power was observed in a case of benzyl amino compound.118  
Shen et al. (2010) worked on hydroxycoumarin Derivatives as novel and potent α-
Glucosidase Inhibitors. Among all hydroxycoumarin derivatives studied, compounds 
44 and 45 exhibited the highest activities, were specific inhibitors of α-glucosidase, 
and could be exploited as the lead compounds for the development of potent α-
glucosidase inhibitors.119 
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4.3.2 Chemistry Aspects of Coumarin 
Seidman et al. (1950) synthesized anticoagulant and rodenticide compounds like, 3-
(α-acetonylbenzyl)-4-hydroxycoumarin in 67% yield by refluxing 4-hydroxycoumarin 
and 4-phenylbutan-2-one in presence of a mixture of dioxane and piperidine.120 Hais 
et al. (1951) first time developed a paper chromatography technique for the analysis 
of 4-hydroxycoumarin derivatives. Here NH3-H2O-butanol or octanol system was 
used for the detection and identification of pelentan and dicoumarol and some of 
their degradation products in blood and urine.121 Knobloch et al. (1953) studied 
infrared spectra of many compounds and based on IR spectra conclude that 
chromone derivative may be responsible for anticoagulant activity.122 Klosa et al. 
(1956) synthesized 4-Acetoxycoumarin, 4-propionyloxycoumarin, and 4-
butyryloxycoumarin; they were subjected to the Fries reaction with several metal 
halides as catalysts and 4-hydroxycoumarin as starting phenol.123 
Indian scientist Bose et al. (1960) developed new method for synthesis of 4-
hydroxycoumarin. They synthesized 4-hydroxy coumarins by heating diaryl 
malonates with equimolor moles of corresponding malonic acid in the presence of 
about anhydrous ZnCl2 and POCI3.
124 Schroeder et al. (1960) proved mechanism of 
formation of warfarin from 4-hydroxy- coumarin and β-anilinobenzylacetone.  They 
conclude that Schiff base intermediates showing enhanced reactivity in the Michael 
reaction.125 
Checchi et al. (1966) synthesized aminomethylene derivatives of 4-hydroxycoumarin 
by aminolysis of 3 substituted derivatives of pyrano(3,2-c)benzopyran-2,5-dione . 
They also prepared Schiff bases from 3-formyl-4-hydroxy-coumarin and the 
corresponding primary amines.126 Reiche et al. (1966) performed condensation 
reaction of alkynols (1-phenylbut-3-yn-1-ol) with 4-hydroxycoumarins in mixture of 
acetic acid with sulphuric acid or AcOH-BFborontrifloride yielded anticoagulants of 
the warfarin type in 70-80% yields. This was first attempt to use alkynol for synthesis 
of anticoagulant compounds.127 
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Kumar et al. (1966) synthesized N-thiocarbamyl derivatives of 3-amino-4-hydroxy 
coumarin by 3-Amino-4-hydroxycoumarin were refluxed with an equivalent amount 
of aryl isothiocyanate in ethanol to give final product.128 Pozetti et al. (1970) were 
identified and characterized 4-hydroxyderivatives by thin-layer chromatography 
They used silica gel HF254-cellulose (1:1) and silica gel G-cellulose (1:1) as stationary 
phase  with mobile phase as  the following 3 solvent systems: 20:3 C6H6-AcOH; 
20:20:6.6:0.7 Me2CO-AcOEt-petroleum ether-H2O; 5:4:1 C6H6-AcOEt-AcOH. The 
plates were developed by spraying a solution of diazotized p-nitroaniline or 0.5% 
KMnO4, and examined under UV light.129 
Kutznetsova et al. (1972) were isolated two compounds of coumarin type from H. 
pedicellatum and IR spectrum was characterized by absorption bands at 3420 and 
1710 cm-1, uv spectrum by absorption max. at 230, 252, 297, and 345 nm; the 
compound proved to be 6-methoxy-7-[(6,7-dihydroxy-3,7-dimethyl-2-octenyl)]oxy-
coumarin (46) by other analytical datas.130 
Mitra et al. (1982) reported [3,3]Sigmatropic rearrangement of allyl ethers of 3-
hydroxycoumarin (47) and synthesized derivatives of 48th compound.131  
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Swaroop et al. (1983) developed a convenient method for the construction of 3,3-
dimethylallyl unit at C-3 of coumarin nucleus and utilized in the synthesis of the title 
compound (49). The synthetic strategy involves condensation of 3-formyl-7-
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benzyloxycoumarin with acetone under acid-catalyzed condition, followed by 
catalytic hydrogenation, Grignard reaction with MeMgI, and dehydration. Finally, 
condensation of 3-(3, 3-dimethylallyl)-7-hydroxycoumarin with 4,4-dimethoxy-2-
methylbutan-2-ol affords the desired compound.132 
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Kappe et al. (1995) synthesized alkylhydroxyquinolinones from 
acylhydroxyquinolones using Zn powder (particle size <45 mm) in acetic acid and 
hydrochloric acid.133 Miky et al. (1995) performed Mannich reaction of 3-
hydroxycoumarin derivatives with various amines in the presence of formaldehyde 
gave corresponding products(50).134 
Zhang et al. (2004) discovered unique reaction of 4-hydroxy-2H-1-benzopyran-2-one 
with 2,5-cyclohexadiene-1,4-dione and pyridine gave [2,5-dihydroxy-6-(4-hydroxy-2-
oxo-2H-1-benzopyran-3-yl)phenyl]pyridinium salt (51). The structures of these 
compound were detected by IR, MS(ESI), 1H NMR, 13C NMR, the single-crystal X-ray 
diffraction.135  
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Fodorv et al. (2005) were synthesized benzopyran derivatives in good yields by the 
reaction of tris[2-(chloromethyl)phenyl]bismuth diacetate and [2-(halomethyl) 
aryl]lead triacetate with phenols and naturally occurring 4-hydroxycoumarins in the 
presence of bases according to a three-step one-pot procedure. Products thus 
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prepared included derivatives of 6H,11H-[2]benzopyrano[4,3-c][1]benzopyran-11-
one, 1,3-dimethoxy-6Hdibenzo[b,d]pyran.136 
Shestopalov et al. (2005) synthesized 2-amino-5-oxo-4,5-dihydropyrano[3,2-
c]chromenes (52) from  4-hydroxycoumarin, carbonyl compounds, and malononitrile 
or alkyl cyanoacetates in ethanol in the presence of triethylamine as a catalyst.137 
Volmajer et al. (2005) performed Knoevenagel reaction between 2-
hydroxybenzaldehydes and active methylene compounds (malononitrile and 
ethylcyano acetate) produced iminocoumarins (53).138 
                      
O
52
O
O
Ar
CN
NH2
                 
O NH
CN
OH
53                            
Abhijit et al. (2006) were synthesized 4-Aryl- and 4-alkylaminocoumarins by reaction 
of 4-hydroxycoumarin with amines under microwave irradiation in solvent-free 
conditions in good to excellent yields.139 
Olga et al. (2006) discovered novel short-step methodology for the synthesis of 
coumarin in good yield starting from an activated precursor, the N-
hydroxysuccinimide ester of O-acetylsalicylic acid. The procedure is based on a 
tandem C-acylation-cyclization process under mild reaction conditions. The structure 
of 3-methoxycarbonyl-4-hydroxy coumarin has been established by X-ray diffraction 
analysis and its geometry was compared with optimized parameters by means of 
DFT calculations.140 Gao et al. (2008) investigated the preparation of 4-
hydroxycoumarin derivatives (54) via heterocyclization of phenol derivatives with 
Meldrum's acid. 141  
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4.3.3 Synthetic Methods of Coumarin 
Coumarin and its derivatives were synthesized by many researchers, using different 
methods. Pechmann142 synthesized coumarin from phenol. Several methods are 
reported for the synthesis of 4-Hydroxy coumarins and their 4-Hydroxy substituted 
derivatives namely: 
1 Perkin143 
2 Anschutz method 144 
3 Pauli Lockemann synthesis 145 
4 Sonn's synthesis 146 
5 Mentzer's synthesis 147 
6 Robertson synthesis 148 
7 Ziegler and Junek method 149 
8 Garden's method 150 
9 Shah, Bose and Shah's method 151 
10 Kaneyuki method 152 
11 Resplandy's method 153 
12 Jain, Rohatagi and Sheshadri's method 154 
13 Shah, Bhatt and Thakor's method 155 
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Pechmann Condensation  
 
 
It is a Condensation reaction that allows synthesis of coumarin by reaction of phenol 
with β-keto esters. 
Mechanism of Pechmann Condensation 
Step 1 
 
 
Step 2 
 
 
Step 3 
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Shah et al.151-155 have prepared 4-Hydroxy coumarin derivatives by condensation of 
different phenols with malonic acid in the presence of zinc chloride and phosphorous 
oxychloride. The method is useful as single step preparation of 4-Hydroxy coumarin 
derivatives substituted in benzenoid part and synthesized in good yield. 
Recently many researchers156-187 have reported synthetic strategies for 4-Hydroxy 
coumarin. 
Y O
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Y O
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methylcyclohexane/  [bmim] [SBF6]
               6:1, 850C, 9hr
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The employment of hydrophobic ionic liquids dramatically enhanced the activity of 
metal triflates in Friedel-Crafts alkenylations of aromatic compounds with various 
alkyl-and aryl-substitutedalkynes.188 
 
 
Arylpropionic acid methyl esters having a MOM-protected hydroxy group at the 
ortho position underwent hydroarylation with various arylboronic acids in methanol 
at ambient temperature in the presence of a catalytic amount of CuOAc, resulting in 
the formation of 4-arylcoumarins in high yields after the acidic workup.189 
 
 
The basic ionic liquid 1-Butyl-3-methylimidazolium hydroxide, [bmim]OH, efficiently 
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catalyzes the Knoevenagel condensation of various aliphatic and aromatic aldehydes 
and ketones with active methylenes at room temperature without requirement of 
any organic solvent.190 
 
 
A facile, convenient, efficient and high yielding synthesis of a combinatorial library of 
3-aroylcoumarins has been developed by the condensation of easily available 
aroylketene dithioacetals and 2-Hydroxybenzaldehydes in the presence of catalytic 
amount of piperidine in THF reflux.191 
 
 
The ionic liquid 1-Butyl-3-methylimidazonium tetrafluoroborate [bmim]BF4 was used 
for Ethylenediammonium diacetate (EDDA)-catalyzed Knoevenagel condensation 
between aldehydes or ketones with active methylene compounds. Catalyst and 
solvent were recyclable.192 
 
 
A new carbamoyl Baker-Venkataraman rearrangement allows a general synthesis of 
substituted 4-Hydroxycoumarins in good overall yields. Intermediate arylketones are 
efficiently prepared via a Directed ortho Metalation - Negishi cross coupling protocol 
from arylcarbamates. The overall sequence provides a regiospecific anionic Friedel-
Crafts complement for the construction of ortho-acyl phenols and coumarins.193 
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An Efficient and Practical Procedure for the Synthesis of 4-Substituted Coumarins.194 
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5. MATERIALS AND METHODS 
All chemicals (Merck UK Pvt. Ltd.) were purchased without any external financial 
support. All materials were stored and utilized for reaction in laboratory of R. K. 
College of Pharmacy, Rajkot. 
Synthesis of intermediates and final products, with high yield in minimum steps, was 
a major concern in this work. Keeping this view in mind, we optimized each step 
during this work. The modifications were made on trial and error basis, applying 
appropriate logic. We have synthesized derivatives of substituted 4-hydroxy 
coumarin nucleus. 
Our target was to synthesize propranolol like molecules, containing coumarin 
skeleton. Hence, in the first step, we synthesized 4-hydroxycoumarin from phenol 
which was then, converted to epoxy derivative in second step. The epoxy derivative 
was reacted with an amine to form alkylaminohydroxypropoxy coumarin derivative 
that was finally converted to its hydrochloride salt. Following synthetic scheme was 
used for reference -   
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Synthetic Scheme 
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5.1.1 Experimental Procedure 
5.1.1.1 Preparation of 4-hydroxy Coumarin Nucleus 
OH
R1
+ CH2 (COOH)2
700
ZnCl2
POCl3
O
OH
R1
R2 R2
R1 = H, CH3
R2 = H, CH3
C
O
55 56 57
 
The coumarin nucleus was prepared according to A. K. Shah and co-worker’s 
method. Phenol (0.1M, 55) and malonic acid (0.1M, 56) were added to a mixture of 
phosphorous oxychloride (40ml) and anhydrous zinc chloride (30g) that was 
preheated to 600C. The reaction mixture was heated for 12-15 hours at 70 0C on 
water bath. After completion of reaction, the reaction mixture was decomposed by 
ice and water to form a yellow solid. This was filtered and washed with water and 
further triturated with 10% w/v sodium carbonate and filtered. The filtrate was 
cooled and slowly acidified with dilute hydrochloric acid. At the neutral point, solid 
product was precipitated, filtered and washed with water followed by drying. The 
product was recrystallized, using dilute ethanol. Reaction yield was 60 % with 
melting point 258-2600C and Rf* value of 0.31. 
*Mobile phase: n-Hexane-Ethyl acetate 1:1 
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5.1.1.2  Preparation of 4-(2, 3-epoxypropoxy) Coumarin  
O
OH
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R2 ClCH2CHCH2
K2CO3
O
O
OCH2CHCH2
R1
R2 OO
O57
58
 
In 100 ml RBF, 4-hydroxy coumarin (0.01M, 57), potassium carbonate (0.02M) and 
epichlorhydrin (15ml) were heated, for 14-18 hours on oil bath. The reaction mixture 
was filtered to remove potassium salts. Filtrate was distilled out. Approximately 7ml 
distillate was collected followed by addition of 25 ml toluene which on distillation 
gave yellow semisolid mass. The product was used for further reaction, without 
isolation.  
5.1.1.3 Preparation of 4-(2-hydroxy-3-isopropylaminopropoxy) Coumarin 
(CH3)2CHNH2
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A mixture of 4-(2, 3-epoxypropoxy) coumarin (0.01 M, 58) and 25ml isopropyl 
alcohol was warmed in 100ml RBF to form solution. 5ml Isopropyl amine was added 
to the reaction mixture and refluxed for 12-15 hours, on a water bath. Under 
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reduced pressure, excess isopropylamine and isopropanol were distilled out to 
produce reddish brown, semisolid mass. This semisolid mass was used for the 
preparation of its hydrochloride salt. 
5.1.1.4 Preparation of 4-(2-hydroxy-3-isopropylaminopropoxy) Coumarin   
hydrochloride 
The base (59) was dissolved in mixture of isopropylalcohol and ether (1:5). This 
solution was chilled at 0-1 0C and dry HCl gas was passed in to the solution under 
stirring. Off- white solid was precipitated from the reaction mixture. Yield of reaction 
was 70% and melting point of synthesized product was 220-222 0C.     
O
O
R1
R2
CH2CCH2NHCH
OH
O
CH3
CH3
O
O
R1
R2
CH2CCH2NHCH
OH
O
CH3
CH3
HCl gas
.HCl
+
59 60
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5.2  PHARMACOLOGICAL SCREENING 
5.2.1 Anticoagulant Activity 
5.2.1.1 Blood sample collection and blood analysis  
For screening of anticoagulant activity, at the end of three weeks treatment, blood 
samples were collected from retro orbital plexuses under light ether anesthesia. The 
samples were collected in EDTA tube to prevent clot formation, at room 
temperature. Determination of clotting time was done by using Lee and White 
method. 
5.2.1.2 Apparatus 
1. Sterile disposable pricking needle  
2. Stop watch 
3. Dry glass capillary tube (narrow diameter 1 top 2 mm, minimum 10 cm long.) 
4. Cotton Swab of absorbent cotton 
5. Spirit wetted cotton swab 
5.2.1.3 Chemicals 
    70 % v/v ethyl alcohol or 70 % v/v denatured spirit. 
5.2.1.4 Stepwise procedure 
1. Blood was collected from retro orbital plexus under light anesthetized condition.  
2. Stop watch was started, immediately. 
3. One end of capillary was dipped into blood drop, without applying pressure. 
5. At every 30 second, a small piece of capillary was broken. Stop watch was used to 
measure the time. 
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6. This process was repeated until fibrin thread appeared, at the broken end of the 
capillary tube. 
7. The time interval was recorded between, pricking the finger and first appearance 
of the fibrin thread. This was noted as the clotting time of blood. 
5.2.1.5 Statistical Analysis 
Results are presented as mean ± SEM.  Statistical differences between the means of 
the various groups were evaluated using one-way analysis of variance (ANOVA) 
followed by Tukey’s test. Data were considered statistically significant at P  0.05 
and highly significant at P  0.001. Statistical analysis was performed using Sigma 
stat statistical software. 
5.2.2 Anti Hypertensive Activity 
5.2.2.1 Apparatus 
1. BIOPAC 
2. Blood pressure coupler 
3. Pair of scissors  
4. Burette 
5.2.2.2 Chemicals 
 1. Noradrenaline  
2. Saline 
3. Ketamine  
4. Diazepam 
5.2.2.3 Stepwise Procedure 
1.  Healthy Wistar male rats (230-250 gm) were anaesthetized with ketamine 
solution.  
2.  A midline incision was made on the skin of neck, starting from the lower end of 
larynx up to the upper end of thorax. Muscles were separated along the midline with 
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the help of pair of scissors by introducing the closed tips. The jugular vein was 
exposed, just under the skin at the side of neck, taking care, not to damage it. 
3.  The venous cannula was inserted into the vein in the same fashion, as into the 
artery, except that the bulldog clamp was first applied proximally and a ligature was 
tied a little distally while, the vein was full of blood.  
4.  After the cannula was tied in position, it was connected to burette filled with 
saline. 
 5.  Drugs were injected through the rubber tubing near to the cannula and a 
constant volume of saline was allowed to run, each time after injection.  
6. Trachea was exposed by retracting the pretracheal muscles, and a transverse cut 
was made in between two rings. A tracheal cannula was introduced into the gap 
between the two rings pointing toward the lung and held firmly in position with the 
help of ligature. The purpose of cannulating the trachea, was to allow free breathing, 
without any obstruction by secretions that can be cleared as and when necessary 
and also to provide artificial respiration, when needed and also to facilitate recording 
of the effects of drugs on respiration.   
7.  Carotid arteries that lie close to the trachea on either side along with the vein and 
the nerves could be easily recognized by their elastic and pulsating nature. One of 
these arteries was cleaned from the accompanying structure, to a sufficient length, 
with the help of a blunt dissector. It was then, tied near the head end, as possible. A 
bulldog clamp was placed, about 3 cm nearer to the head and thread was passed 
around the artery.  
8.  A cut was made carefully on the artery, close to the ligature, with the help of a 
sharp curved scissors so as to make a small opening through which, an arterial 
cannula already filled with some coagulant fluid, was inserted directing towards the 
heart, and firmly secured with the ligature, already in position.  
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9. Arterial cannula was connected to the three-way tap in manometer. The space 
between the manometer and the arterial cannula was filled with sodium citrate. 
Care was taken to avoid entry of any air bubble.  
10. When the whole system was ready, and rendered free of air bubbles, the 
pinchcock was closed. The pressure in the manometer was then, increased to about 
150 mmHg and then three way knob was turned so that the manometer was in 
communication with the cannula. The positive pressure was approximately equal to 
that of the blood pressure of the animal. Before the bulldog clamp was removed, 0.5 
ml of heparin solution was injected in to the arterial cannula through the rubber 
tubing. The bulldog clamp was then taken off; the column of mercury rose or fell, 
slightly, until its pressure counterbalanced that of the blood. The writing points 
remained at a constant level, except for slight oscillation, due to the heart beats and 
respiratory movements. The height of the mercury column, midway between the top 
and the bottom of these oscillations, was taken as the mean arterial pressure. 
5.2.2.4 Statistical Analysis 
Results were presented as mean ± SEM.  Statistical differences between the means 
of the various groups were evaluated using one-way analysis of variance (ANOVA) 
followed by Tukey’s test. Data were considered statistically significant at P  0.05. 
Statistical analysis was performed using Sigma stat statistical software. 
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6. RESULT 
In the present project, we synthesized 30 drug molecules, with antihypertensive 
activity of propranolol and anticoagulant activity of Warfarin. To achieve this, we 
attached alkylaminohydroxypropoxy side chain to 4-hydroxy coumarin nucleus. 
6.1 PHYSICAL DATA  
The syntheses involved following steps: 
1. Preparation of 4-hydroxy coumarin nucleus 
2. Preparation of 4-(2, 3-epoxypropoxy) coumarin  
3. Preparation of 4-(2-hydroxy-3-alkylaminopropoxy) coumarin 
4. Preparation of 4-(2-hydroxy-3-alkylaminopropoxy) coumarin hydrochloride 
 
6.1.1  Physical Data of Substituted 4-Hydroxycoumarin 
O O
R2
OH
R1
 
The completion of reaction was checked by TLC (n-Hexane-Ethyl acetate 1:1). 4-
hydroxy coumarin was freely soluble in methanol and chloroform and yellowish in 
color. 
Table 3: Physical Data of Synthesized Coumarin Nucleus  
Sr. No Code R1 R2 M.F. 
M. P. 
(0C) 
Rf *value Color % Yield 
1 BST 11 H H C9H6O3 258-260 0.31 Yellow 60 
2 BST 21 -CH3 H C10H8O3 271-273 0.26 Yellow 54 
3 BST 31 H -CH3 C10H8O3 278-280 0.28 Yellow 57 
 
*Mobile phase: n-Hexane-Ethyl acetate 1:1 
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Fig. 2 FTIR Spectra of BST 11 
BST 11   
O
OH
O
 
6.1.2 FTIR Spectra of Synthesized Coumarin Nucleus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. No. Wave number (Cm-1) Remarks 
1 1705 -C=O (S) 
2 1161 -C-O (S) 
3 3113 -O-H (S) 
4 1593 -C=C (S) 
Table: 4 FTIR Spectral Data of BST 11 
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Sr. No. Wave number (Cm-1) Remarks 
1 1705 -C=O (S) 
2 1147 -C-O (S) 
3 3106 -O-H (S) 
4 1556 -C=C (S) 
5 2981 -C-H (Ar) (S) 
Table 5: FTIR Spectral Data of BST 31 
Fig. 3 FTIR Spectra of BST 31 
BST 31 
O O
OH
H3C
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Table 6: Physical Data of 4-(2-hydroxy-3-isopropylaminopropoxy) coumarin 
hydrochloride 
 
6.1.3 Physical Data of 4-(2-hydroxy-3-isopropylaminopropoxy) Coumarin 
hydrochloride 
O
O
R2
CH2CHCH2NH
OH
O
R3 .HCl
+
R1
 
 
 
 
Sr. 
No 
Code R1 R2 R3 M.F. M. P.(
°C) 
Rf * 
value 
%Yield 
1 BLT 1 H H -CH(CH3)2 
C15H20NO4 
Cl 
220-222 0.37 60 
2 BLT 2 H H -C(CH3)3 
C16H22NO4 
Cl 
212-214 0.35 68 
3 BLT 3 H H -CH2(CH2)2CH3 
C16H22NO4 
Cl 
218-220 0.33 62 
4 BLT 4 H H -CH2(CH2)3CH3 
C17H24NO4 
Cl 
228-230 0.33 58 
5 BLT 5 H H -CH(CH2)2 
C15H18NO4 
Cl 
222-224 0.33 54 
6 BLT 6 H H -CH(C2H2)5 
C18H24NO4 
Cl 
230-232 0.28 54 
7 BLT 7 H H -(C2H5)2 
C16H22NO4 
Cl 
226-228 0.35 62 
8 BLT 8 H H -(C2H40H)2 
C16H22NO6 
Cl 
218-220 0.39 61 
9 BLT 9 H H -(C4H9)2 
C20H30NO4 
Cl 
225-227 0.28 54 
10 BLT 10 H H -(CH3)2 
C14H18NO4 
Cl 
220-222 0.35 52 
11 BLT 11 -CH3 H -CH(CH3)2 
C16H22NO4 
Cl 
245-247 0.31 56 
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12 BLT 12 -CH3 H -C(CH3)3 
C17H24NO4 
Cl 
240-242 0.30 59 
13 BLT 13 -CH3 H -CH2(CH2)2CH3 
C17H24NO4 
Cl 
247-249 0.25 61 
14 BLT 14 -CH3 H -CH2(CH2)3CH3 
C18H26NO4 
Cl 
259-261 0.27 53 
15 BLT 15 -CH3 H -CH(CH2)2 
C16H20NO4 
Cl 
251-253 0.31 55 
16 BLT 16 -CH3 H -CH(C2H2)5 
C19H26NO4 
Cl 
261-262 0.25 48 
17 BLT 17 -CH3 H -(C2H5)2 
C17H24NO4 
Cl 
270-272 0.31 50 
18 BLT 18 -CH3 H -(C2H40H)2 
C17H24NO6 
Cl 
258-260 0.40 38 
19 BLT 19 -CH3 H -(C4H9)2 
C21H32NO4 
Cl 
270-272 0.25 47 
20 BLT 20 -CH3 H -(CH3)2 
C15H20NO4 
Cl 
262-264 0.31 38 
21 BLT 21 H -CH3 -CH(CH3)2 
C16H22NO4 
Cl 
251-253 0.31 50 
22 BLT 22 H -CH3 -C(CH3)3 
C17H24NO4 
Cl 
244-246 0.24 48 
23 BLT 23 H -CH3 -CH2(CH2)2CH3 
C17H24NO4 
Cl 
251-253 0.28 47 
24 BLT 24 H -CH3 -CH2(CH2)3CH3 
C18H26NO4 
Cl 
263-265 0.28 45 
25 BLT 25 H -CH3 -CH(CH2)2 
C16H20NO4 
Cl 
257-259 0.33 46 
26 BLT 26 H -CH3 -CH(C2H2)5 
C19H26NO4 
Cl 
245-247 0.28 45 
27 BLT 27 H -CH3 -(C2H5)2 
C17H24NO4 
Cl 
278-280 0.35 48 
28 BLT 28 H -CH3 -(C2H40H)2 
C17H24NO6 
Cl 
258-260 0.41 38 
29 BLT 29 H -CH3 -(C4H9)2 
C21H32NO4 
Cl 
270-272 0.28 43 
30 BLT 30 H -CH3 -(CH3)2 
C15H20NO4 
Cl 
265-267 0.25 36 
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6.2 SPECTRAL DATA 
6.2.1 IR Spectra 
Synthesized compounds conformed to the spectral analysis. Infra Red Spectra were 
taken on Shimadzu FT-IR-8400 Spectrometer, using KBr Pellet method. The 
characteristic peak of carbonyl group in coumarin moiety was observed at 1700-
1722 cm-1 frequency, while C-O streching of  ring skeleton was observed at 1160-
1125 cm-1 frequency. The N-H streching of secondary amine gave a broad peak, 
between 3350-3300 cm-1 frequency. The C-N streching was observed at 1250-1235 
cm-1 frequency. The –OH bending was observed at 1380-1310 cm-1 frequency. Other 
frequencies, observed due to ring skeleton, were around 1600-1450 cm-1 frequency 
of C=C stretching and 2900-3000 cm-1 frequency, was due to C-H stretching 
6.2.2 Mass Spectra 
Further conformation of the molecular structure was evaluated by mass spectra. The 
mass spectrum of compounds were recorded by Shimadzu GC-MS-QP-2010 
spectrometer. The molecular ion peak and the base peak, in all compounds, were 
clearly obtained in mass spectral study. The molecular ion peaks were found to be in 
agreement with molecular weight of the respective compounds. 
6.2.3 1H NMR Spectra 
1H NMR Spectra were recorded on a Bruker AC 400 MHz NMR Spectrometer using 
MeOD as solvent. In the NMR spectra of 4-(2-hydroxy-3-tertiarybutyl aminopropoxy) 
coumarin various proton values of methylene (-CH2), amine (>NH), Hydroxy (R-OH) 
methyl (-CH3) and aromatic protons (Ar-H) etc. were observed as under. 
NMR Spectrum of compound BLT2, was taken which showed methylene (-CH2), 
amine (>NH), hydroxy (R-OH) methyl (-CH3) and aromatic protons (Ar-H) peaks. The 
values for methylene (-CH2) proton was observed between 2.77 and 2.86 δ ppm. 
Aromatic protons showed the multiplet between 7.35-8.05 δ ppm. The singlet peak 
of  amine (-NH) was observed at  3.88-3.91 δ ppm. The value of methyl proton (-CH3) 
was observed as singlet at 1.18 δ ppm. Multiplet were observed at 4.26-4.29 ppm of 
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(-CH2CHCH2) proton and triplet was obtained at 4.16-4.22 ppm due to (-CH2CH) 
group. 
O
O
O CH2
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CH3
CH3
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9 10
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Fig. 4 FTIR Spectra of BLT 5 
BLT 5 
O
OCH2CHCH2NHCH2(CH2)3CH3
O
OH
6.2.4 FTIR SPECTRA OF SYNTHESIZED COMPOUNDS  
 
 
 
 
 
 
 
 
 
 
 
 
Table.7 FTIR Spectral Data of BLT 5 
Sr. No. Wave number (Cm-1) Remarks 
1 2864 -C-H (s) 
OCH2CHCH2NHCH2(CH2)3CH3
OH  
2 1287 -C-N (s) 
3 3417 N-H (s) 
4 1319 -OH(b) 
5 1056 -C-O (S) 
6 767 -C-O (b) 
7 1694 -C=O (S) 
O O
 
8 1151 -C-O (S) 
9 2960 -C-H (Ar) (S) 
10 1566 -C=C (S) 
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Sr. No. Wave number (Cm-1) Remarks 
1 2976 -C-H (s) 
OCH2CHCN
OH
C2H5
C2H5  
2 1245 -C-N (s) 
3 1393 -OH(b) 
4 1038 -C-O (S) 
5 746 -C-O (b) 
6 1721 -C=O (S) 
O O
 
7 1160 -C-O (S) 
8 3033 -C-H (Ar) (S) 
9 1566 -C=C (S) 
Table 8: FTIR Spectral Data of BLT 8 
BLT 8 
Fig. 5 FTIR Spectra of BLT 8 
O
OCH2CHCH2N
O
OH
C2H5OH
C2H5OH
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Sr. No. Wave number (Cm-1) Remarks 
1 2869 -C-H (s) 
OCH2CHCH2NHCH2(CH2)3CH3
OH  
2 1103 -C-N (s) 
3 3418 N-H (s) 
4 1315 -OH(b) 
5 1034 -C-O (S) 
6 1721 -C=O (S) 
O O
CH3
 
7 1152 -C-O (S) 
8 2962 -C-H (Ar) (S) 
9 1581 -C=C (S) 
Table 9:  FTIR Spectral Data of BLT 12 
BLT 12 
Fig. 6 FTIR Spectra of BLT 12 
O
OCH2CHCH2NHCH2(CH2)3CH3
O
CH3
OH
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Sr. No. Wave number (Cm-1) Remarks 
1 2820 -C-H (s) 
OCH2CHCH2N
OH
C4H9
C4H9  
2 1243 -C-N (s) 
3 1393 -OH(b) 
4 1047 -C-O (S) 
5 773 -C-O (b) 
6 1717 -C=O (S) 
O O
CH3
 
7 1160 -C-O (S) 
8 2970 -C-H (Ar) (S) 
9 1559 -C=C (S) 
Table 10: FTIR Spectral Data of BLT 19 
BLT 19 
Fig. 7 FTIR Spectra of BLT 19 
O
OCH2CHCH2N
O
OH
C4H9
C4H9
CH3
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Sr. No. Wave number (Cm-1) Remarks 
1 2942 -C-H (s) 
OCH2CHCH2NHCH2(CH2)2CH3
OH  
2 1247 -C-N (s) 
3 3357 -N-H (s) 
4 1326 -OH(b) 
5 1036 -C-O (S) 
6 763 -C-O (b) 
7 1718 -C=O (S) 
O OH3C
 
8 1146 -C-O (S) 
9 3081 -C-H (Ar) (S) 
10 1563 -C=C (S) 
Table 11:  FTIR Spectral Data of BLT 23 
Fig. 8 FTIR Spectra of BLT 23 
BLT 23 
O O
OCH2CHCH2NHCH2(CH2)2CH3
H3C
OH
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Sr. No. Wave number (Cm-1) Remarks 
1 2974 -C-H (s) 
OCH2CHCH2NH(C2H5)2
OH  
2 1246 -C-N (s) 
3 1382 -OH(b) 
4 1038 -C-O (S) 
5 747 -C-O (b) 
6 1721 -C=O (S) 
O OH3C
 
7 1137 -C-O (S) 
8 3033 -C-H (Ar) (S) 
9 1568 -C=C (S) 
Table 12: FTIR Spectral Data of BLT 27 
Fig. 9 FTIR Spectra of BLT 27 
 BLT 27 
O OH3C
OCH2CHCH2N(C2H5)2
OH
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Sr. No. Wave number (Cm-1) Remark 
1 2978 -C-H (s) 
OCH2CHCN
OH
C2H5OH
C2H5OH
 
2 1245 -C-N (s) 
3 1379 -OH(b) 
6 1720 -C=O (S) 
O OH3C
 
7 1137 -C-O (S) 
8 3256 -C-H (Ar) (S) 
9 1566 -C=C (S) 
Table 13:  FTIR Spectral Data of BLT 28 
Fig. 10 FTIR Spectra of BLT 28 
BLT 28 
O OH3C
OCH2CHCHNH2
OH
C2H5OH
C2H5OH
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BLT 1 
Figure 11:  Mass Spectra of BLT 1 
O
OCH2CHCH2NHCH
O
CH3
CH3
OH
HCl
+
+
6.2.5 MASS SPECTRA OF SYNTHESIZED COMPOUNDS 
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Sr. No. Structure m/e 
1 
O
OCH2CHCH2NHCH
O
CH3
CH3
OH
HCl
+
+
 
312.5 
2 
O
OCH2CHCH2NHCH
O
CH3
CH3
OH
Cl
+
 
311.5 
3 
O
OCH2CHCH2
O
OH
+
 
219 
4 
O
OCH2
O
+
 
175.0 
5 
O
O
O
+
 
161.0 
Table 14: Mass Spectral Data of BLT 1 
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Figure 12:  Mass Spectra of BLT 2 
BLT 2 
O
OCH2CHCH2NH
O
OH
+
HCl
M Wt: 326.5
C
CH3
CH3
CH3 .
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Table 15: Mass Spectral Data of BLT 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. No. Structure m/e 
1 
O
OCH2CHCH2NH
O
OH
+
HClC
CH3
CH3
CH3
+
 
326.5 
2 
O
OCH2CHCH2NH
O
OH
+
ClC
CH3
CH3
CH3
+
 
325.5 
3 
O
OCH2CHCH2NH
O
OH
C
CH3
CH3
CH3
+
 
291 
4 
O
OCH2CHCH2NH
O
OH
+
 
234 
5 
O
O
O
+
 
161.0 
                                                                                                        Result 
Page 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
OCH2CHCH2NH
O
OH
+
HCl
M Wt: 353.5
BLT 6  
Figure 13:  Mass Spectra of BLT 6 
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Sr. No. Structure m/e 
1 
O
OCH2CHCH2NH
O
OH
+
+
HCl
 
353.5 
2 
O
OCH2CHCH2NH
O
+
 
300 
3 
O
OCH2CHCH2NH
O
+
 
216 
4 
O
O
O
+
 
161 
Table 16: Mass Spectral Data of BLT 6 
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Figure 14:  Mass Spectra of BLT 7 
BLT 7 
O
OCH2CHCH2N
O
OH
C2H5
C2H5
HCl
M Wt: 327.5
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Sr. No. Structure m/e 
1 
O
OCH2CHCH2N
O
OH
C2H5
C2H5
HCl
+
+
 
327.5 
2 
O
OCH2CHCH2N
O
OH
C2H5
C2H5
+
 
291 
3 
O
OCH2CHCH2N
O
C2H5
C2H5
+
 
274 
4 
O
OCH2CCH2N
O
C2H5
+
 
245 
5 
O
OCH2CCH2N
O
+
 
216 
6 
O
OCH2CCH2
O
+
 
202 
7 
O
OCH2
O
+
 
175 
 
 
Table 17: Mass Spectral Data of BLT 7 
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Figure 15:  Mass Spectra of BLT 8 
BLT 8 
O
OCH2CHCH2N
O
OH
HCl
M Wt: 358.5
C2H4OH
C2H4OH
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Sr. No. Structure m/e 
1 O
OCH2CHCH2N
O
OH
HCl
C2H4OH
C2H4OH
 
353.5 
2 
O
OCH2CHCH2N
O
OH
C2H4OH
C2H4OH
 
323 
3 
O
OCH2CHCH2N
O
OH
C2H4OH
 
278 
4 
O
OCH2CHCH2N
O
C2H4OH
 
261 
5 
O
OCH2
O
 
175 
6 
O
O
O
 
161 
 
 
 
Table 18: Mass Spectral Data of BLT 8 
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BLT 18 
Figure 16:  Mass Spectra of BLT 18 
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Sr. No. Structure m/e 
1 
O
OCH2CHCH2N
O
OH
C2H4OH
C2H4OH
HCl
H3C
+
 
373.5 
2 
O
OCH2CHCH2N
O
OH
C2H4OH
C2H4OH
H3C
+
 
337 
3 
O
OCH2CHCH2N
O
OH
H3C
+
 
247 
4 
O
OCH2CHCH2
O
OH
H3C
+
 
233 
5 
O
OCH2CHCH2
O
OH
+
 
218 
 
 
 
Table 19: Mass Spectral Data of BLT 18 
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BLT 21 
O
OCH2CHCH2NHCH
O
OH
HCl
M Wt: 327.5
CH3
CH3
H3C
Figure 17:  Mass Spectra of BLT 21 
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Sr. No. Structure m/e 
1 
O
OCH2CHCH2NHCH
O
OH
HCl
CH3
CH3
H3C
+
 
327.5 
2 
O
OCH2CHCH2NHCH
O
CH3
CH3
+
 
261 
3 
O
OCH2CHCH2
O
+
 
203 
4 
O
OCH2
O
+
 
176 
5 
O
O
O
+
 
164 
Table 20: Mass Spectral Data of BLT 21 
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Fig. 18 NMR Spectra of BLT 2 
Table.21 NMR Spectral Data of BLT 2 
 
 
Sr. No. Signal Position (δ ppm) Multiplicity Inference 
1 1.16 Singlet -CH3 
2 2.77-2.86 Doublet -CH2-NH 
3 3.88 Singlet -NH 
4 4.16-4.22 Triplate -CH2CH 
5 4.26-4.29 Multiplet -CH2CHCH2 
6 4.88 Singlet -CH in ring (coumarin) 
7 5.86 Singlet -OH 
8 7.35-8.00 Multiplet Ar-H 
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6.3  PHARMACOLOGICAL SCREENING 
6.3.1  Bleeding Time and Clotting Time 
Warfarin- treated (0.1mg/kg p.o.) rats showed significant increase in bleeding and 
clotting time, as compared to normal control rats. Treatment with, all 15 test 
compounds (5ml/kg/day, p.o) also produced significant increase in bleeding and 
clotting time, as compared to normal control rats.  
Table 22: Effect of Warfarin and  BLT 1,2,7,8,10,11,12,17,18,20,21,22,27,28,30 Treatment on 
Bleeding and Clotting Times of Rats.   
 
Blood 
parameters 
Bleeding 
Time (sec) 
Clotting 
Time (sec) 
Normal 80+ 12 130+ 22 
Warfarin 190+ 18 # 390+ 35 # 
BLT 1 162 + 34 * 331 + 37 * 
BLT 2 186 + 27 # 371 + 23 # 
BLT 7 143 + 41 289 + 39 
BLT 8 180 + 35 # 363 + 26 # 
BLT 10 133 + 46 278 + 56 
BLT 11 148 + 25 310 + 20 
BLT 12 176 + 28 # 365 + 37 # 
BLT 17 146 + 37 322 + 43 
BLT 18 176 + 43 # 362 + 30 # 
BLT 20 152 + 24 * 335 + 52 * 
BLT 21 145 + 35 331 + 47 * 
BLT 22 170 + 23 # 356 + 52 * 
BLT 27 149 + 35 * 320 + 37 
BLT 28 171 + 12 # 358 + 29 # 
BLT 30 144 + 39 325 + 43 
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Values are expressed as Mean + S.E.M 
*- significantly different from control (p < 0.05), # - significantly different from 
control (p < 0.01) 
Above data indicates that a change in the chemical structure of coumarin does not 
alter its anti-coagulant activity. 
 
Fig. 19 Anticoagulant Screening of Synthesized Compounds 
 
6.3.2  Antihypertensive Screening:   
9 anticoagulant compounds were subjected to antihypertensive screening. Here, 
noradrenalin-treated (10mg/kg i. v.) rats showed significant increase in blood 
pressure. Treatment with test compounds (5mg/kg/day, IV) also produced 
antihypertensive action, but BLT 1, 2, 21 had significant effect as compared to 
others. 
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Table 23: Pharmacological Screening of Antihypertensive Activity  
Drug 
Blood pressure (mmHg) 
Normal 
Nor-adrenaline 
(NA) 
Test compound 
+ NA 
Difference 
BLT-1 120 208 + 5 166 + 14 * 42 
BLT-2 122 215 + 7 173 + 13 * 42 
BLT-7 116 210 + 6 187 + 17 23 
BLT-11 122 210 + 10 192 + 15 18 
BLT-12 120 208 + 7 180 + 14 28 
BLT-17 120 236 + 5 208 + 16 28 
BLT-21 120 208 + 8 154 + 17 * 54 
BLT-22 120 208 + 9 180 + 18 28 
BLT-27 120 236 + 11 210 + 16 26 
*- significantly different from control (p < 0.05)  
 
 
 
 
 
 
 
 
 
 
Figure 21: Pharmacological Screening of Antihypertensive Activity   
 
We infer that, Isopropylamine side chain may play an important role in 
antihypertensive activity of the compound.  
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6. DISCUSSION 
Since, hypertension and thrombo-embolism are intricately involved in pathophysiological 
changes and progression of cardio-vascular diseases; antihypertensive drugs like 
propranolol and anticoagulant drugs like warfarin (a coumarin derivative) are frequently, 
combined in management of some types of hypertension. Therefore, in the present project, 
we attempted to synthesize a single drug molecule with antihypertensive activity of 
propranolol and anticoagulant activity of Warfarin. To achieve this, we attached 
alkylaminohydroxypropoxy side chain (responsible for antihypertensive activity of 
propranolol) to 4-Hydroxy coumarin nucleus (responsible for anticoagulant activity of 
warfarin).  
In our project, for synthesis of substituted 4-hydroxy coumarin nucleus, we used phenol, m-
cresol and p-cresol as starting materials. Thus, we synthesized 3 basic coumarin nucleus viz. 
4-hyddroxy coumarin, 7-methyl-4-hydroxy coumarin and 8-methyl-4-hydroxy coumarin 
nucleus, respectively. Each nucleus was then, reacted with epichlorhydrin to form three 
varieties of epoxy derivatives. Finally, each epoxy derivative was reacted with 10 different 
amines to form 10 different coumarin molecules. All these, 30 compounds were then, 
converted to hydrochloride salts by reacting them with dry hydrochloric acid gas.  
The syntheses involved following steps: 
1. Preparation of 4-hydroxy coumarin nucleus 
2. Preparation of 4-(2, 3-epoxypropoxy) coumarin  
3. Preparation of 4-(2-hydroxy-3-alkylaminopropoxy) coumarin 
4. Preparation of 4-(2-hydroxy-3-alkylaminopropoxy) coumarin hydrochloride 
 
1. Preparation 4-hydroxy coumarin nucleus   
AS per literature report, we found that phenol reacts with malonic acid and 
phosphorusoxychloride in presence of anhydrous zinc chloride give 4-hydoxy coumarin. 
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OH
+ CH2 (COOH)2
700C
ZnCl2
POCl3
O
OH
O
R2 R2
R1 R1
 
For synthesis of 4-hydroxy coumarin, we followed new method developed by Indian 
scientist Bose et al. They synthesized 4-hydroxy coumarins by heating diaryl malonates with 
equimolor moles of corresponding malonic acid in the presence of about anhydrous ZnCl2 
and POCI3. We attempted to carry out this reaction at 70
0C for 12-15 hours, but it was 
observed that maximum yield was obtained only after 16 hours. It was also noted that on 
acidification of sodium bicarbonate filtrate, at neutral point, the product precipitated out. 
The yield was increased, if acidified slurry was kept overnight. Hence, this modified version 
of reaction was adopted for synthesis of all other coumarin derivatives in our project. Our 
attempts to carry out reactions of other phenols like α-napthol, β-napthol and hydroxyl 
benzoic acid were unsuccessful. 
 
2. Preparation of 4-(2, 3-epoxypropoxy) coumarin  
 
O
OH
R2 ClCH2CHCH2
K2CO3
O
O
O
OCHCH2
R2 O
CH2
O
R1
R1
 
When 4-hydroxy coumarin derivative was treated with epichlorhydrine in presence of base, 
under suitable condition, resulted in formation of the epoxy derivative. To obtain solid 
product, the epoxy resin was completely separated from reaction mixture, by using mother 
solvent i.e. toluene. This was dissolved in a minimum quantity of dioxane and was slowly 
poured on to crushed ice with vigorous stirring. Thus, solid epoxy derivative was isolated. 
Attempt to use benzene instead of toluene failed to produce a solid product. 
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3. Preparation of 4-(2-hydroxy-3-isopropylaminopropoxy) coumarin 
(CH3)2CHNH2
O
O
R2
CH2CHCH2NHCH
OH
IPA
O
CH3
CH3
O
OCHCH2
R2 O
CH2
O
R1
R1
R1
 
In this step, the epoxy derivative was treated with an amine to form a product. This reaction 
was also successful if Iso- Propyl Alcohol (IPA) was used as a solvent.  Semisolid mass was 
obtained only, when the solvent or unreacted amine was distilled out. When this product 
was dissolved in 1:5 mixture of DMF + dioxane then poured on to ice + water mixture, a free 
product (base) in aqueous medium obtained. But when it was filtered, it soon converted in 
to brown semisolid mass. 
   
4. Preparation of 4-(2-hydroxy-3-isopropylaminopropoxy) coumarin hydrochloride 
O
O
R2
CH2CHCH2NHCH
OH
O
CH3
CH3
HCl
O
O
R2
CH2CCH2NHCH
OH
O
CH3
CH3
R1
HCl
+
R1
R1
 
The base was dissolved in appropriate solvent and converted in to hydrochloride salt and 
isolated as a white solid product. To dissolve semisolid base, we used different solvent 
mixtures, in different proportions and then treated with dry hydrochloric acid gas to obtain 
the corresponding free hydrochloride. Solvent mixtures used were (A) Methanol + 
Diethylether (B) Isopropanol + Ethylacetate (C) Isopropanol + Diethylether (D) Isopropanol + 
Diethylether. But all these solvent mixtures proved to be unsuccessful except, Isopropanol + 
Diethylether (1:3) mixture.  
 
Synthesized compounds conformed to the spectral analysis. IR spectral characteristic peak 
of carbonyl group, in coumarin moiety, was observed at 1700-1722 cm-1frequency, while C-
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O streching of ring skeleton was observed at 1160-1125 cm-1 frequency. The N-H streching 
of secondary amines gave a broad peak between 3350-3300 cm-1 frequency. The molecular 
ion peak and the base peak, in all compounds, were clearly obtained in mass spectral study. 
NMR Spectra of compound BLT2, were taken which showed methylene (-CH2), amine (>NH), 
hydroxy (R-OH) methyl (-CH3) and aromatic protons (Ar-H) etc. peaks. 
 
When subjected to pharmacological screening for anticoagulant activity and 
antihypertensive activity; all 12 synthesized compounds exhibited anticoagulant activity but 
highly significant anticoagulant activity was observed in compounds BLT 2, 8, 12, 18, 28 
accompanied by increased bleeding and clotting time that was near to the standard drug viz. 
Warfarin, indicating that 6-methyl and 7-methyl derivatives also possess anticoagulant 
activity. Substituted groups that contain four carbon atoms, if substituted at nitrogen atom, 
exhibit maximum activity. This goes to confirm that 4-hydroxycoumarin derivatives, have 
anticoagulant property and that there is no relation between substituted and unsubstituted 
coumarin derivatives. We believe that in coumarin class anticoagulant compounds, hydroxyl 
group of 4-Hydroxy coumarin plays important role in formation of cyclic structure through 
hydrogen bond, with side chain attached to 3rd carbon in coumarin nucleus eg. warfarin. In 
case of our compounds, hydrogen bond formation takes place between hydroxyl group of 
side chain and pi-electrons of alkene in coumarin ring (3rd and 4th carbons) hence; cyclic 
structure is formed showing activity in all compounds that were tested. 
We believe that bulkier substitution on 3rd position of coumarin causes increase in 
anticoagulant activity, e.g. ferulenol. In our project, we found that more bulky groups like 
tert-butyl (BLT 1) showed significant anticoagulant activity. Diethanol derived compounds 
BLT 8 and BLT 18, showed good activity for the same reason. Finally, we conclude that 
formation of ring structure in coumarin through hydrogen bonding and bulky groups at 
terminal part of the side chain are responsible for anticoagulant activity, in a compound.    
Compounds BLT 1, 2, 7, 11, 12, 17, 21, 22, 27 were evaluated for antihypertensive activity, by using 
invasive method on BioPac instrument. Results showed that Isopropyl and tert-butyl 
substituted compounds i.e. BLT 1, 2, 21 possess significant antihypertensive activity. We infer 
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that increase in the carbon length more than four on amine substitution causes decrease in 
antihypertensive activity. 
Thus, we synthesized 30 coumarin derivative compounds, out of which, 12 compounds 
exhibited anticoagulant activity, 9 among which also exhibited antihypertensive activity. 
Some of these 9 compounds, with dual activity, were 7-methyl substituted coumarin and 8-
methyl coumarin too. 3 compounds among these were Isopropyl and tert-butyl substituted 
compounds possessing significant antihypertensive activity. 
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7. CONCLUSION 
In the present project, we have synthesized 30 coumarin derivative compounds, out of 
which, 12 compounds exhibited anticoagulant activity, 9 among which also exhibited 
antihypertensive activity. Some of these 9 compounds, with dual activity, were 7-methyl 
substituted coumarin and 8-methyl coumarin too. 3 compounds among these were 
Isopropyl and tert-butyl substituted compounds possessing significant antihypertensive 
activity. Literature review reveals that carbon no. 7 in coumarin nucleus of Warfarin is 
involved in its metabolism, before being excreted in urine. Hence, metabolism studies of 
these compounds may be planned as an extension of our work.   
In the light of above work, we conclude that in coumarin class anticoagulant 
compounds, hydroxyl group of 4-Hydroxy coumarin plays important role in formation of 
cyclic structure through hydrogen bond, with side chain attached to 3rd carbon in 
coumarin nucleus e.g. Warfarin. We also infer that formation of ring structure in 
coumarin through hydrogen bonding and bulky groups at terminal part of the side chain 
are responsible for anticoagulant activity, in a compound. Our results also indicate that 
increase in the carbon length more than four on amine substitution causes decrease in 
antihypertensive activity. 
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ANTICOAGULANT ACTIVITY OF SUBSTITUTED HYDROXY 
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Summary 
Coumarin molecule is used as anticoagulant. Other uses like anti-HIV, anti-tumor, anti-
hypertensive, anti-arrhythmia, anti-osteoporosis, pain relief increase research of coumarin 
derivatives. Perkin discovered the synthetic method of coumarin and opened the door in 
synthetic research. Warfarin is a well known drug of 4-hydroxy coumarin derivative. It is 
consider that, warfarin drug act as a lead molecule of anticoagulant. To introduce 
alkylaminohydroxypropoxy side chain in coumarin nucleus changes its anticoagulant 
activity. Hence we have synthesized substituted coumarin derivatives and performed its 
anticoagulant activity.  
Key words 
Warfarin, Coumarin derivative, Anticoagulant 
Introduction 
Thromboembolism is the combination of thrombosis and its main complication, 
embolism. When a thrombus occupies more than 75% of surface area of the lumen of an 
artery, blood flow to the tissue supplied is reduced enough to cause symptoms because of 
decreased oxygen (hypoxia) and accumulation of metabolic products like lactic acid. 
More than 90% obstruction can result in anoxia, the complete deprivation of oxygen, and 
infarction, a mode of cell death [1]. 
The symptoms of a thromboembolism depend on the organ or blood vessel that has lost 
blood supply. Blood clots in an arm or leg may cause pain, swelling, and increased 
temperature in the affected area. A clot that travels to the lung is called a pulmonary 
embolus. This condition can cause: chest pain, shortness of breath, rapid heartbeat, 
known as tachycardia, fainting or death. If a blood clot is formed in the heart, it can travel 
to almost any organ in the body. This could cause a stroke, which is a type of damage to 
the brain from lack of blood circulation. In other cases, damage may be done to an arm or 
leg, or a heart attack or kidney damage may occur. Other areas of the body can also be 
affected [2].  
An anticoagulant is a substance that prevents coagulation; that is, it stops blood from 
clotting. Anticoagulants were introduced into medical practice more than three decades 
ago. Extensive use of these drugs in the prevention and treatment of thromboembolic 
disease has made them one of the most widely used classes of pharmacological agents.  
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Anticoagulant drugs include: Heparin and derivative substances e.g. Low molecular 
weight heparin and Coumarins (Vitamin K antagonists) e.g. Warfarin [3].  
Warfarin acts via inhibition an enzyme vitamin K epoxide reductase, which recycles 
oxidized vitamin K to its reduced form after it has participated in the carboxylation of 
several blood coagulation proteins, mainly prothrombin and factor VII [4]. Reduced 
vitamin K must be regenerated from the epoxide for sustained carboxylation and 
synthesis of biologically competent proteins [5]. So we have tried to synthesize coumarin 
derivative which posse’s anticoagulant activity.  
Coumarin derivatives are used as therapeutic anticoagulants and as rodenticides by 
causing fatal haemorrhage [6]. Because the range between efficient therapy and undue 
hemorrhagic risk may vary greatly from one patient to another, the need for carefully 
individualized treatment and frequent observations has long been stressed. However, a 
summary of recent research findings, along with certain principles, may offer possible 
explanations for responsiveness to make highly efficient lead with fewer side effects to 
resist both, coagulopathy as well as hypertension. The primary aim of this present work is 
to study pharmacological screening and synthetic aspects of the coumarin ring structure 
especially its combined analogues profile as an anticoagulant and antihypertensive 
property. Our first aim is to study anticoagulant activity of synthesized compounds and 
then work on antihypertensive parameters. 
Materials and Method 
Sterile disposable pricking needle or lancet, stop watch, dry glass capillary tube (narrow 
diameter 1 top 2 mm, minimum 10 cm long), cotton swab of absorbent cotton, spirit 
wetted. 70 % v/v ethyl alcohol or 70 % v/v denatured spirit is used as antiseptic. 
Blood sample collection and blood analysis: Blood samples were collected in clean dry 
centrifuge tubes as end of three weeks of treatment after 12hrs fast from retro orbital 
plexuses under light ether anesthesia and were collected in EDTA tube to prevent clot 
formation at room temperature.  
Determination of clotting time using Lee and white method. 
Experimental: 
We have synthesized a series of 4-substituted coumarin derivatives and performed its 
pharmacological screening for anticoagulant activity. 4
th
 position is substituted with 
alkylaminohydroxypropoxy side chain. 
Blood was collected from animal by retro orbital plexus method under light anesthetic 
conditions. Immediately stop watch was started. Dip one end of capillary into blood drop 
gently without pressure. After every 30 seconds, using stopwatch, break a small piece of 
capillary. Repeat breaking at regular time intervals, till fibrin thread appears at broken 
end of capillary tube. Do not pull away the cut pieces ling apart and bristly. Record time 
interval between pricking finger and first appearance of fibrin thread at the broken ends 
of capillary tube. That is clotting time of blood. 
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Statistical analysis: Results are presented as mean ± SEM.  Statistical differences 
between the means of the various groups were evaluated using one-way analysis of 
variance (ANOVA) followed by Tukey’s test. Data were considered statistically 
significant at P  0.05 and highly significant at P  0.001. Statistical analysis was 
performed using Sigma stat statistical software. 
 
Result and Discussion 
 
 
 
Warfarin treated (0.1mg/kg p.o.) rats were found to be shown significant increase in 
bleeding and clotting time as compare to normal healthy rat. Treatment with tested 
compounds (5ml/kg/day, p.o) also produced significant increase in bleeding and clotting 
time as compared to normal rats. It may be act same as warfarin, but it is confirmed that 
change in chemical structure of coumarin side chain altered its anti-coagulant activity. 
Coumarin nucleus is responsible for anticoagulant activity. While side chain play 
important role in other activity like hypertension, arrhythmia etc. Our first aim is 
synthesized anticoagulant compound which posses antihypertensive activity. Primary 
screening for anticoagulant activity is performed while other activity will perform as 
early as possible. 
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Summary 
Tremendous research on coumarin derivatives and anticoagulant drug are main 
inspiration of this work. Methylated coumarin derivative substituted by 
alkylaminohaydroxypropoxy side chain gives antihypertensive as well as anticoagulant 
activities. Therefore, in the present project, we attempted to synthesize a single drug 
molecule with antihypertensive activity of propranolol and anticoagulant activity of 
warfarin (coumarin).  
Key words 
Anticoagulant, methylated coumarin, antihypertensive 
Introduction 
It may be a first attempt to work on coumarin derivative as antihypertensive agent. Blood 
is a specialized bodily fluid that delivers necessary substances to the body's cells – such 
as nutrients and oxygen – and transports waste products away from those same cells. 
Blood is composed of blood cells suspended in a liquid called blood plasma. Plasma, 
which comprises 55% of blood fluid, is mostly water (90% by volume) and contains 
dissolved proteins, glucose, mineral ions, hormones, carbon dioxide (plasma being main 
medium for excretory product transportation), platelets and blood cells themselves. The 
blood cells present in blood are mainly red blood cells (also called RBCs or erythrocytes) 
and white blood cells, including leukocytes and platelets. The most abundant cells in 
human blood are red blood cells. These contain hemoglobin, an iron-containing protein, 
which facilitates transportation of oxygen by reversibly binding to this respiratory gas 
and greatly increasing its solubility in blood. In contrast, carbon dioxide is almost entirely 
transported extracellular dissolved in plasma as bicarbonate ion [1].  
Blood diseases affect the production of blood and its components, such as blood cells, 
hemoglobin, blood proteins, mechanism of coagulation, etc. Thrombosis is formation of a 
blood clot (thrombus) inside a blood vessel, obstructing flow of blood through circulatory 
system. When a blood vessel is injured, body uses platelets and fibrin to form a blood 
clot, because first step in repairing it (hemostasis) is to prevent loss of blood. If that 
mechanism causes too much clotting, and clot breaks free, an embolus is formed. This 
plug obstructs normal flow of blood and can result in a heart attack or stroke [2]. 
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Warfarin is coumarin containing anticoagulant. The story of the coumarin anticoagulants 
generally is traced back to the early 1920s, when the "sweet clover disease" showed up 
almost simultaneously in North Dakota and in Alberta, Canada. This new malady of 
cattle involving fatal bleeding was traced to stacks of sweet clover hay [3].
 
An 
anticoagulant is a substance that prevents coagulation; that is, it stops blood from 
clotting. Anticoagulants were introduced into medical practice more than three decades 
ago. Extensive use of these drugs in the prevention and treatment of thromboembolic 
disease has made them one of the most widely used classes of pharmacological agents. 
Antiplatelet agents, anticoagulant agents and thrombolytic drugs use as antithrombic 
agent.  
Coumarins are a group of important natural compounds, and have been found to have 
multi-biological activities such as anti-HIV, anti-tumor, anti-hypertensive, anti-
arrhythmia, anti-osteoporosis, pain relief, preventing asthma and antisepsis [4]. Natural 
products like esculetin, fraxetin, daphnetin and other related coumarin derivatives are 
recognized as inhibitors not only of the lipoxygenase and cycloxygenase enzymic 
systems, but also of the neutrophil-dependent superoxide anion generation. Coumarin 
derivatives also possess anti-inflammatory as well as antioxidant activities. Coumarin 
possesses immunomodulatory and direct antitumor activity [5]. It has been recommended 
for treatment of a number of clinical conditions, including high protein oedema and 
brucellosis. Coumarin and some of its derivatives have been tested for treatment of 
anxiolytic, microcirculation disorders and angiopathic ulcers, and also for treatment of 
high protein oedemas in animals [6].  
Materials and Methods 
Sterile disposable pricking needle, stop watch, dry glass capillary tube (narrow diameter 
1 top 2 mm, minimum 10 cm long), cotton swab, spirit wetted, 70 % v/v ethyl alcohol. 
Blood sample collection and blood analysis: Blood samples were collected in clean dry 
centrifuge tubes as end of three weeks of treatment after 12hrs fast from retro orbital 
plexuses under light ether anesthesia and were collected in EDTA tube to prevent clot 
formation at room temperature.  
We have used Lee and white method for determination of clotting time. 
Experimental 
We have synthesized a series of methylated coumarin substituted derivatives and 
performed its pharmacological screening for anticoagulant activity. 4
th
 position is 
substituted with alkylaminohydroxypropoxy side chain as in propranolol. 
Blood was collected from animal by retro orbital plexus method under light anesthetic 
conditions. Immediately stop watch was started. Dip one end of capillary into blood drop 
gently without pressure. After every 30 seconds, using stopwatch, break a small piece of 
capillary. Repeat breaking at regular time intervals, till fibrin thread appears at broken 
end of capillary tube. Do not pull away the cut pieces ling apart and bristly. Record time 
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interval between pricking finger and first appearance of fibrin thread at the broken ends 
of capillary tube. That is clotting time of blood. 
Statistical analysis: Results are presented as mean ± SEM.  Statistical differences 
between the means of the various groups were evaluated using one-way analysis of 
variance (ANOVA) followed by Tukey’s test. Data were considered statistically 
significant at P  0.05 and highly significant at P  0.001. Statistical analysis was 
performed using Sigma stat statistical software. 
 
Result and Discussion 
We have synthesized a series of coumarin derivative. This may possess antihypertensive 
activity too.  
O
O
R1
R2
CH2CHCH2NH
OH
O
R3 .HCl
+
 
Tab: 1 Synthesized compounds  
Sr. 
No 
Code R1 R2 R3 M.F. 
M. P. 
(
°
C) 
Rf* 
value 
% 
Yield 
1 BLT 11 -CH3 H -CH(CH3)2 C16H22NO4 Cl 245-47 0.31 56 
2 BLT 12 -CH3 H -C(CH3)3 C17H24NO4 Cl 240-42 0.30 59 
3 BLT 17 -CH3 H -(C2H5)2 C17H24NO4 Cl 270-72 0.31 50 
4 BLT 18 -CH3 H -(C2H40H)2 C17H24NO6 Cl 258-60 0.40 38 
5 BLT 20 -CH3 H -(CH3)2 C15H20NO4 Cl 262-64 0.31 38 
6 BLT 21 H -CH3 -CH(CH3)2 C16H22NO4 Cl 251-53 0.31 50 
7 BLT 22 H -CH3 -C(CH3)3 C17H24NO4 Cl 244-46 0.24 48 
8 BLT 27 H -CH3 -(C2H5)2 C17H24NO4 Cl 278-80 0.35 48 
9 BLT 28 H -CH3 -(C2H40H)2 C17H24NO6 Cl 258-60 0.41 38 
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10 BLT 30 H -CH3 -(CH3)2 C15H20NO4 Cl 265-67 0.25 36 
 
Warfarin treated (0.1mg/kg p.o.) rats were found to be shown significant increase in 
bleeding and clotting time as compare to normal healthy rat. Treatment with tested 
compounds (5ml/kg/day, p.o) also produced significant increase in bleeding and clotting 
time as compared to normal rats. We have not found it’s mechanism but it is confirmed 
that change in chemical structure of coumarin side chain altered its anti-coagulant 
activity. Coumarin nucleus is responsible for anticoagulant activity. While side chain 
play important role in other activities like hypertension, arrhythmia etc. Our first aim is 
synthesized anticoagulant compound which posses antihypertensive activity. Our work 
may helpful to discover the new series of drug use in hypertension.   
Tab: 2 Effect of warfarin and synthesized compounds on bleeding and clotting times on 
rats.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Values are expressed as Mean + S.E.M 
*- significantly different from control (p < 0.05), # - significantly different from control 
(p < 0.01) 
Blood 
parameters 
Bleeding 
Time (sec) 
Clotting 
Time (sec) 
Normal 80+ 12  130+ 22 
Warfarin 190+ 18 
#
 390+ 35 
#
 
BLT 11 148 + 25 310 + 20 
BLT 12 176 + 28 
#
 365 + 37 
#
 
BLT 17 146 + 37  322 + 43 
BLT 18 176 + 43 
#
 362 + 30 
#
 
BLT 20 152 + 24 * 335 + 52 * 
BLT 21 145 + 35 331 + 47 * 
BLT 22 170 + 23 
#
 356 + 52 * 
BLT 27 149 + 35 * 320 + 37 
BLT 28 171 + 12 
#
 358 + 29 
#
 
BLT 30 144 + 39 325 + 43 
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Fig: 1 Pharmacological Screening of anticoagulant activity 
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ABSTRACT: 
Coumarin molecule is used as anticoagulant. Other uses like anti-HIV, anti-tumor, anti-
hypertensive, anti-arrhythmia, anti-osteoporosis, pain relief increase research of coumarin 
derivative. Perkin discovered a synthetic method of coumarin and opened the door in 
synthetic research. Now a days there are so many methods are use to form coumarin. 
Warfarin is a well known drug of 4-hydroxy coumarin derivative. It is consider that, 
propranolol drug act as a lead molecule of β-blocker. Alkylaminohydroxypropoxy side 
chain is responsible for β-blocking activity in propranolol. Hence synthesis and it’s 
characterization of antihypertensive coumarin derivative was our main target. 
 
 
KEY WORD:  
Coumarin, Anticoagulant, antihypertensive agent, Alkylaminohydroxypropoxy 
 
INTRODUCTION: 
Coumarin is a widely occurring secondary metabolite that occurs naturally in several 
plant families and essential oils. Coumarin is an  anhydride of o-coumaric acid having 
white, crystalline lactone, obtainable naturally from  several  plants,  such  as  tonka  
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bean,  lavender, sweet  clover  grass,  apicots, cherries, strawberries,  and cinnamon. It is 
also synthesized from an amino acid, phenylalanine.
 [1] 
Coumarins are a group of important natural compounds, and have been found to have 
multi-biological activities such as anti-HIV, anti-tumor, anti-hypertensive, anti-
arrhythmia, anti-osteoporosis, pain relief, preventing asthma and antisepsis.
 [2]
 Natural 
products like esculetin, fraxetin, daphnetin and other related coumarin derivatives are 
recognized as inhibitors not only of the lipoxygenase and cycloxygenase enzymic 
systems, but also of the neutrophil-dependent superoxide anion generation. Coumarin 
derivatives also possess anti-inflammatory as well as antioxidant activities. Coumarin 
possesses immunomodulatory and direct antitumor activity. 
[3]
 It has been recommended 
for treatment of a number of clinical conditions, including high protein oedema and 
brucellosis. Coumarin and some of its derivatives have been tested for treatment of 
anxiolytic, microcirculation disorders and angiopathic ulcers, and also for treatment of 
high protein oedemas in animals. 
[4]
 
Coumarin derivatives are used as therapeutic anticoagulants and as rodenticides by 
causing fatal haemorrhage. Because the range between efficient therapy and undue 
hemorrhagic risk may vary greatly from one patient to another, the need for carefully 
individualized treatment and frequent observations has long been stressed. However, a 
summary of recent research findings, along with certain principles, may offer possible 
explanations for responsiveness to make highly efficient lead with fewer side effects to 
resist both, coagulopathy as well as hypertension. The primary aim of this present work is 
to study pharmacological and synthetic aspects of the coumarin ring structure especially 
its combined analogues profile as an anticoagulant and antihypertensive property.  
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The interesting biological properties of coumarin made these compounds very attractive 
for organic synthesis. Perkin discovers the synthetic method of coumarin and till today 
thousands of compounds were synthesized. Other named reactions for coumarin synthesis 
are Pechmann reaction, Knoevenagel reaction, Wittig reaction, Kostanecki-Robinson 
reaction and Reformatsky reaction. 
[5]
 Bose and his colleague discover a new method for 
synthesis of 4-hydroxy coumarin from substituted phenol. 
[6]
 
Warfarin is 4-hydroxy coumarin derivative and used as anticoagulant agent. Warfarin 
mainly acts via inhibition an enzyme vitamin K epoxide reductase that recycles oxidized 
vitamin K to its reduced form after it has participated in the carboxylation of several 
blood coagulation proteins, mainly prothrombin and factor VII. 
[7]
 Propranolol is a lead 
molecule of non-selective β-blockers. It is a derivative of alkylaminohydroxypropoxy 
side chain, which is responsible for antihypertensive activity. This side chain also affect 
pharmacokinetic and pharmacodynemic properties of drugs. 
[8]
 
The main complications of hypertension, i.e. coronary heart disease, ischemic strokes and 
peripheral vascular disease are usually related to thrombosis. It therefore seems plausible 
that use of antithrombotic therapy may be of particular benefit in preventing the 
thrombosis-related complications of elevated blood pressure. 
[9]
 Therefore our aimed was 
to synthesize coumarin derivatives which may be use as antihypertensive agent. 
 
RESULT AND DISCUSSION 
Synthesis of following compounds was performed. Coumarin moiety plays important role 
in anticoagulation of blood and sidechain has antihypertensive property. So following 
compounds are novel series of coumarin derivatives may be used as antihypertensive 
agent. 
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Table.1: Physical characteristics data of synthesized compounds 
Sr. 
No 
Code R1 R2 R3 M.F. 
M. P. 
(
°
C) 
Rf * 
value 
% 
Yield 
1 BLT 1 H H -CH(CH3)2 C15H20NO4Cl 220-22 0.37 60 
2 BLT 2 H H -C(CH3)3 C16H22NO4Cl 212-14 0.35 68 
3 BLT 3 H H -CH2(CH2)2CH3 C16H22NO4 Cl 218-20 0.33 62 
4 BLT 4 H H -CH2(CH2)3CH3 C17H24NO4 Cl 228-30 0.33 58 
5 BLT 5 H H -CH(CH2)2 C15H18NO4 Cl 222-24 0.33 54 
6 BLT 11 -CH3 H -CH(CH3)2 C16H22NO4 Cl 245-47 0.31 56 
7 BLT 12 -CH3 H -C(CH3)3 C17H24NO4 Cl 240-42 0.30 59 
8 BLT 13 -CH3 H -CH2(CH2)2CH3 C17H24NO4 Cl 247-49 0.25 61 
9 BLT 14 -CH3 H -CH2(CH2)3CH3 C18H26NO4 Cl 259-61 0.27 53 
10 BLT 15 -CH3 H -CH(CH2)2 C16H20NO4 Cl 251-53 0.31 55 
11 BLT 21 H -CH3 -CH(CH3)2 C16H22NO4 Cl 251-53 0.31 50 
12 BLT 22 H -CH3 -C(CH3)3 C17H24NO4 Cl 244-46 0.24 48 
13 BLT 23 H -CH3 -CH2(CH2)2CH3 C17H24NO4 Cl 251-53 0.28 47 
14 BLT 24 H -CH3 -CH2(CH2)3CH3 C18H26NO4 Cl 263-65 0.28 45 
15 BLT 25 H -CH3 -CH(CH2)2 C16H20NO4 Cl 257-59 0.33 46 
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During synthesis many problems were solved by trial and error methods to increase yield. 
In step one increase the yield by maintain temperature at 65-70 
0
C. Purification is 
required in step one, so we tried to purify this products using ethanol: chloroform (9:1) 
mixture by recrystaliastion method. Epoxy derivatives are formed by using 
epichlorhydrin in presence of potassium carbonate as a base. At higher temperature sticky 
products were obtained. Hence this reaction was carried out at 120-125 
0
C. To get solid 
product, the epoxy resin was completely separated by using mother solvent i.e. toluene 
and then dissolved in a minimum quantity of dioxane which was slowly poured in to 
crushed ice with vigorous stirring and solid epoxy derivative was isolated. Here we have 
also used benzene in place of toluene but product was not solidified after pour in to 
crushed ice.  
Here epoxy derivative is treated with amine give final product. This reaction was also 
successful if IPA used as solvent.  If solvent or unreacted amine was distilled out then 
sticky semisolid mass was obtained, so hydrochloric acid salt formation was preferable 
solution to convert in to solid. This product was hygroscopic and protect from moisture. 
Synthesized compounds shown in table 1.  Here tert-butyl amine gives highest yield 
among this series. 
Synthesized compounds were structurally evaluated using spectroscopic methods like, 
IR, Mass and NMR techniques. In FTIR analysis, a peak was observed at 1700 cm
-1 
of 
carbonyl group, C-O streching of ring skeleton was observed at 1160-1125 cm
-1
. The N-
H streching of secondary amines gives  a broad peak between 3350-3300 cm
-1
. The –OH 
bending observed at 1380-1310 cm
-1
. Other frequencies observed due to ring skeleton are 
around 1600-1450 cm
-1 
of C=C
 
stretching. Figure 1 show FTIR spectra of BLT2 
compounds. 
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Figure.1:  FTIR Spectra of BLT2 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectra also give structural information of synthesized compound. BLT1 compound 
was characterized by mass spectra. It shows peak at 311.5 m/z as M-1and other 
fragments’ peak at 219, 175 and 161 m/z. Same fragmentation patterns were observed for 
all synthesized compounds. 
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Figure.2: Mass spectra of BLT1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NMR spectra was taken and singlet peaks are observed at 1.16.of –CH3 of sidechain, 3.88 
of amine, 5.86 of –OH, 4.88 of –CH2 of ring skeleton, while multiplate, triplate and 
doublet  peaks are also observed. 
 
 
 
 
O
OCH2CHCH2NHCH
O
M Wt: 312.5
CH3
CH3
OH
+
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Figure. 3: NMR Spectra of BLT2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION: 
Synthesis and structural characterization of novel derivatives, together with the 
development of new synthetic methods and increase the yield, will be the useful research 
in thromoembolism and hypertension conditions. It is a first approach to synthesize 
alkylaminohydroxypropoxy derivative of coumarin. We conclude that tert-butyl 
derivative is formed in higher yield which may posse’s antihypertensive and warfarin like 
activity. 
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